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Abstract 
Long lead times and large development cost has led the pharmaceutical industry to evaluate 
and improve pharmaceutical development and manufacturing procedures. Emphasis has been 
placed on the connection between drug development and discovery, especially on characterization of 
candidate drugs earlier in drug development. High throughput screens yield multiple solid forms of 
candidate drugs that are later characterized and prioritized for further development. Another focus 
within the pharmaceutical industry has been to improved manufacturing practices with continuous 
manufacturing and online monitoring for quality control. Additive manufacturing, where drugs are 
assembled layer-by-layer, is a technique used to improve process development. 
Microfluidics platforms have been validated for high throughput crystallization of 
pharmaceutical solid form screening of polymorphs, salts, and cocrystals, however the solid forms 
obtained are often poor quality crystals that can only be characterized by vibrational spectroscopy 
(e.g,. infrared or Raman). In this work X-ray compatible microfluidic platforms were develop for on-
chip characterization. Crystal growth was controlled by on-chip crystal seeding. This allowed for 
controlled growth of only one polymorph and growth of large diffraction quality crystals. 
Diffraction data was collected from crystals residing within the chip and the resulting crystal 
structure had similar resolution to the previously reported structures. This work validates the use of 
X-ray characterization on-chip.  
Solid form screens of two model systems, piroxicam cocrystals and clofazimine salts, were 
conducted on and off-chip. The goal of this work was to determine (1) if microfluidic platforms 
would lead to good quality crystals suitable for X-ray diffraction and (2) if microfluidic platforms 
could facilitate solid form discovery. Concentration and solvent were varied to elucidated different 
crystal structures. Four solid forms of piroxicam cocrystals were identified via the on-chip screen. 
Three of the solid forms were good enough crystals for X-ray diffraction, and two of those solid 
forms had not been identified in off-chip experiments. Four solid forms of clofazimine salts were 
observed, three were grown in traditional glass vials and one was grown in a microfluidic platform. 
Three of the solid forms had not been previously reported including the solid form grown in the 
microfluidic platform. Both works yielded the discovery and crystal structure of solid forms from 
crystals grown within a microfluidic platform. This work emphasizes the need for multiple 
crystallization techniques used for high throughput screening of pharmaceuticals, possibly including 
the use of microfluidic platforms. 
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Meniscus-guided coating was explored as an additive manufacturing technique to make 
pharmaceutical thin films. Crystalline films were grown on a biocompatible polymer substrate and 
characterized by polarized optical microscopy to determine the film morphology and X-ray 
diffraction (powder and grazing incidence) to determine the molecular packing. Process parameters 
such as concentration of drug in solution and shearing speed were varied resulting in changes in the 
film morphology, thickness, and polymorph. Aspirin thin films displayed spherulitic and oriented 
morphology, however the molecular packing was of both morphologies was consistent with the 
reported crystal structure for aspirin. Films of ellipticine, a model drug, were found to also display 
multiple morphologies, and again the molecular packing of the different morphologies was the same. 
However, the ellipticine films did not match the reported crystal structure, the films pack in a 
second polymorph of ellipticine. Through this work meniscus-guided coating was a useful technique 
for growing thin pharmaceutical films and controlling the molecular arrangement of the model 
drugs. Meniscus-guided coating can expand the manufacturing approaches for pharmaceutical 
additive manufacturing. 
 
  
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family. 
  
v 
 
Acknowledgements 
 This work would not have been possible without the support, guidance, and encouragement 
of many people. First, I would like to thank my advisor, Dr. Paul J.A. Kenis, for his help navigating 
the ups and down of my graduate school journey. I thank him for been a constant supporter of my 
professional and personal development though graduate school. He has challenged me to become an 
independent thinker and strive toward excellence in anything I undertake. I would also like to 
acknowledge the support of Dr. Ying Diao, who provided me with an enormous amount of support 
and has treated me like one of her own students. I appreciate the great example she sets as an 
advisor and mentor. 
 I would like to thank Dr. Sachit Goyal who helped train me during my first year of graduate 
research. My undergraduate researcher assistants Lucas Gonzalez, Eric Kim, and Yifu Zhang were 
instrumental in the completion of my experimental research and success of my projects. 
Experimental help and support from Dr. Fengjiao Zhang, Tim Chung, Ge Qu, and Erfan 
Mohammadi was greatly appreciated.  
 Support from the Support for Under-Represented Groups in Engineering Fellowship 
Program and the National Science Foundation Graduate Research Fellowship Program helped fund 
my graduate studies and provided freedom to pursue interesting research directions. I would also 
like to acknowledge AbbVie Inc. who sponsored my first year of research. Working with Dr. 
Yuchuan Gong and Dr. Geoff G.Z. Zhang provided insight into real issues in pharmaceutical 
crystallization. Both contributed greatly to my development as an independent researcher. A recent 
collaboration with Dr. Rahul Keswani and Dr. Gus Rosania at the University of Michigan has led to 
some interesting work on biocrystallization, I thank them for the support and input on our work 
together. I would like to thank Dr. Danielle Grey, Dr. Jeffery Bertke, and Dr. Toby Woods from the 
School of Chemical Sciences X-ray Lab. All have been exceedingly helpful with crystal structure 
determination and ideas for growing better crystals. I greatly appreciate their patience with me and 
my unconventional crystallization platforms. 
 Lastly, I would like to thank all of the friends I have made throughout my graduate career; 
they have contributed to so many happy memories. Through the Graduate Committee in the Society 
of Women Engineers I have met inspirational women who have become great friends. Hector, my 
fiancée, is a constant source of support who was always there with a helping hand and a loving 
word. My parents and brother have supported and continue to motivate me throughout my career.  
vi 
 
Table of Contents 
 
1. Chapter 1: Introduction 
1.1  Solid Form Screening ............................................................................................................................................. 2 
1.2  Microfluidic Platforms for Solid Form Screening ............................................................................................. 4 
1.3  Additive Manufacturing of Pharmaceuticals ...................................................................................................... 5 
1.4  Meniscus-guided Coating for Additive Manufacturing .................................................................................... 6 
1.5  References ................................................................................................................................................................ 7 
2. Chapter 2: X-ray Compatible Microfluidic Platforms 
2.1  Introduction ............................................................................................................................................................. 9 
2.2  Experimental ......................................................................................................................................................... 11 
2.3  Results ..................................................................................................................................................................... 15 
2.4  Conclusion ............................................................................................................................................................. 19 
2.5  References .............................................................................................................................................................. 21 
3. Chapter 3: Microfluidic Platforms for Solid Form Discovery 
3.1  Introduction ........................................................................................................................................................... 22 
3.2  Experimental ......................................................................................................................................................... 24 
3.3  Results ..................................................................................................................................................................... 26 
3.4  Conclusion ............................................................................................................................................................. 33 
3.5  References .............................................................................................................................................................. 35 
4. Chapter 4: Biomimetic Crystallization and Solid Form Screen 
4.1  Introduction ........................................................................................................................................................... 36 
4.2  Experimental ......................................................................................................................................................... 37 
4.3  Results ..................................................................................................................................................................... 39 
4.4  Conclusion ............................................................................................................................................................. 49 
4.5  References .............................................................................................................................................................. 51 
5. Chapter 5: Additive Manufacturing of Pharmaceuticals by Meniscus-
guided Coating 
5.1  Introduction ........................................................................................................................................................... 53 
vii 
 
5.2  Experimental ......................................................................................................................................................... 54 
5.3  Results ..................................................................................................................................................................... 56 
5.4  Conclusion ............................................................................................................................................................. 61 
5.5  References .............................................................................................................................................................. 63 
6. Chapter 6: Conclusions and Future Directions 
6.1  Expanding Microfluidic On-chip Characterization ......................................................................................... 64 
6.2  Microfluidics for Solid Form Screening ............................................................................................................ 64 
6.3  Solid Form Screening for Biomimetic Crystals ................................................................................................ 65 
6.4  Microfluidic Implementation in the Pharmaceutical Industry ....................................................................... 66 
6.5  Meniscus-guided Coating for Additive Manufacturing .................................................................................. 66 
6.6  Future Directions of Meniscus-guided Coating for Pharmaceuticals .......................................................... 67 
6.7  References .............................................................................................................................................................. 68 
7. Appendix 
A.1  Platform Fabrication and Assembly .................................................................................................................. 69 
A.2  Biocrystals .............................................................................................................................................................. 70 
A.3  Ellipticine Polymorph II ...................................................................................................................................... 74 
 
 
 
1 
 
Chapter 1 
Introduction 
The estimated cost of drug development has increased from $138 million to $1.3 billion 
from 1975 to 2005.1, 2 Increasing development costs and long turnaround times have led to an 
increased focus during drug discovery to ensure viability of the drug candidate prior to bringing the 
drug to market.3 In the early stages of drug discovery thousands of candidate drugs are screened for 
desirable physiochemical, biopharmaceutical, toxicity, and efficacy. Through this process thousands 
of candidate drugs are eliminated in from the development pipeline (Figure 1.14, image adapted).5 
During the pre-clinical stage the candidate drugs are screened for scalability, intellectual property, 
and economic impact. Only few candidate drugs make it past the clinical studies and are federally 
approved. While more than 50% of the candidate drugs entering clinical trials are lost due to efficacy 
and safety concerns, nearly 40% are lost to patent issues and poor biopharmaceutical and 
physiochemical properties.6 The biological efficacy of an active pharmaceutical ingredient (API) is 
determined by the nature of the interaction with the physiological target (e.g., receptors and 
enzymes). However, the ability to synthesize, store, and administer the drug to the patient in a safe, 
stable, and cost effective manner depends largely on the material properties of the API.6-8 
Oral administration of pharmaceuticals is the preferred route when developing a 
conventional dosage for a new drug. In 2015, 53% of novel drugs approved by the United States 
Federal Drug Administration (U.S. FDA) were orally administered, with injectable making up 40%, 
and other making up 7%. Although oral dosages can be formulated in several ways, about 60% of 
orally administered new drugs are solids (tablets, capsule, and powder).9-12 The percentage of solid 
dosage forms for novel drugs approved by the U.S. FDA has been between 54-70% from 2012-
2015. Solid formulation is advantageous because it is often more stable than liquid counterparts, 
APIs are often manufactured, transported, and sold as solids, and manufacturing capacity to form 
tablets, capsules, and powders is in place. 
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1.1 Solid Form Screening 
To strengthen the discovery and development interface, a ‘developability’ screen has been 
implemented.3, 13 The screen allows for sufficient pre-clinical studies to determine the 
physiochemical properties of candidate drugs. The knowledge gained during the discovery phase 
screen is used to develop drug formulations, storage, and delivery strategy.3 Ultimately the screen 
allows researchers to prioritize the selection of candidate drugs based on their probability of success 
and their potential for returns. Several physiochemical properties assessed during the developability 
screen are: solubility, ionization constant, surface activity, and stability. The aforementioned 
properties are dictated by the molecular interactions within the solid form. Candidate drugs can 
crystallize into multiple solid forms including polymorphs (same molecules with different molecular 
packing), cocrystals (multi-component solid with non-covalent interaction between candidate drug 
and small molecule), salt (multi-component solid with a proton transfer between the candidate drug 
and small molecule), solvate/hydrate (non-ionic multi-component solid with candidate drug and 
solvent or water), Figure 1.214, image adapted. To complicate the crystallization even further, salts, 
cocrystals, and solvates/hydrates can also exist as different polymorphs. It is advantageous to 
elucidate many solid forms to allow for better selection of the candidate drug, and to remove the 
possibility of forming a more thermodynamically stable solid form later in drug development. 
Additionally, if a candidate drug does not crystallize it can be formulated as an amorphous material 
(no long range order) and the physiochemical properties of the material will be different than the 
crystalline solid forms. 
Figure 1.1. Pharmaceutical drug development pipeline showing the attrition of candidate 
compounds throughout the different stages of development.  
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Often, the solid forms of a candidate drug are screened using solution-based crystallization. 
Crystallization occurs when a solution is supersaturated (the concentration of the solute in solution 
is higher than the solubility limit). Techniques to supersaturate a solution include anti-solvent 
addition, solvent evaporation, and heating/cooling of the solution. In each of these routes, the rate 
of supersaturation is a critical factor that can lead to different crystallization outcomes. The 
candidate drug will be crystallized with different solvents, at different concentrations, and in the 
presences of different small molecules. The physiochemical properties of the resulting solid forms 
will be characterized. The solid forms are typically characterized with optical microscopy to note the 
crystallinity of the sample, crystal habit, crystal color, and average crystal size. Vibrational 
spectroscopy (IR or Raman) is commonly used to identify solid forms, and when the spectrum does 
not match any reported spectra a new solid form is identified.  
Figure 1.2. Diagram illustrating the wide variety of solid forms that can be used to formulate  
pharmaceuticals.  
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Solid form screening is limited by the quantity of material present at early stages in drug 
discovery (~ several milligrams) and time consumption for large number of screening conditions. 
An ideal screen would require small amounts of material while maintaining a high level of accuracy 
in testing. Manual screening is often performed; however it is time consuming and subject to error 
in measurements. Large robotic fluid handling systems designed for high throughput screens have 
shown to perform more screening conditions and require smaller amounts of material.7, 15, 16 
However, the large robotic systems are expensive and do not provide the flexibility sometimes 
needed to induce crystallization for some drug candidates. An ideal screening technology would 
require minimal amounts of material, allow for high throughput screens, allow for easy 
characterization of solid forms, be easy to use and implement, and be adaptable to multiple 
crystallization routes. An enhanced screening technology could be instrumental in early stage drug 
discovery.  
1.2 Microfluidic Platforms for Solid Form Screening 
Microfluidic platforms that utilize less material per condition screened and are compatible 
with analytical techniques (e.g., optical microscopy, Raman spectroscopy, and X-ray diffraction) may 
be able to facilitate early solid form screening. Progress in microfluidics has resulted in the 
development of microfluidic platforms for pharmaceutical crystallization of different solid forms, 
such as polymorphs, salts, and cocrystals.17-24 Utilization of microfluidic platforms allows for solid 
form screening at earlier stages of drug development when much smaller quantities of APIs are 
available. For example, platforms based on droplets,21, 23 patterned surfaces,24 free interface 
diffusion,18, 20 antisolvent addition,17 temperature control,22 and evaporation19 have been employed 
for pharmaceutical crystallization. Some of the aforementioned platforms allow for crystal 
harvesting and subsequent analysis via traditional approaches25-27 and some allow for on-chip 
characterization which eliminates the need for manual crystal harvesting. 18, 19, 28-30 In prior work, the 
Kenis group developed microfluidic platforms for pharmaceutical solid form screening employing 
FID, antisolvent addition, and solvent evaporation that allow for solid form identification via on-
chip Raman spectroscopy.17-20 Part of the work described in this thesis focused on comparing on-
chip and off-chip crystallization outcomes to ensure that similar solid forms can be generated in 
both approaches.31, 32 On-chip the crystallization occurred more frequently and the crystals that were 
obtained were higher quality than the crystals obtained during the off-chip experiments. The rate of 
supersaturation on-chip is slower compared to the off-chip experiments resulting in better crystals. 
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In the previous work, Raman spectroscopy was the analytic technique used to differentiate solid 
forms on-chip, but this technique cannot provide structural information. Microfluidic platforms 
comprised of X-ray transparent materials have been use for crystallization screening and X-ray data 
collection for protein crystals on-chip.28-30, 33 To move toward discovery and characterization of 
novel solid forms, microfluidic platforms need to be compatible with X-ray diffraction. It is 
imperative that the composition and structure of the solid form is known before moving to the next 
stage of development. Single crystal X-ray diffraction is the best way to determine the composition 
and structure of a solid form, but this technique requires a pristine crystal larger than 30 µm not 
typically obtained in a high throughput screen.34 A microfluidic approach for pharmaceutical solid 
form screening that (1) enables crystallization optimization by crystal seeding and (2) allows for on-
chip X-ray data collection from crystals formed on-chip is described. The microfluidic seeding 
approach was validated using a model drug, carbamazepine, and a model cocrystals, carbamazepine 
/ 4-hydroxy benzoic acid. 
Previous work validated that microfluidic platform can be used for crystallization screens. In 
this work, I will use microfluidic platforms for solid form discovery. In this work, a cocrystal screen 
was performed using a simple microfluidic platform. This single well platform simulates the 
experimental conditions of a 96 well plate (typically used for high-throughput screening), while 
utilizing less mass of sample per condition screened and providing more control over the rate of 
solvent evaporation. A model cocrystal, piroxicam / 2,5-dihydroxybenzoic acid was chosen since 3 
solid forms were identified, but no crystal structures were reported.35 In this work a solvent and 
concentration screen led to the discovery and of new cocrystals. 
 1.3 Additive Manufacturing of Pharmaceuticals 
The US FDA has encouraged pharmaceutical companies to improve product quality by 
focusing on process development and manufacturing.36 These efforts have stimulated innovation in 
more efficient pharmaceutical manufacturing processes, one of which being the implementation of 
additive manufacturing techniques. Additive manufacturing is a general term used to describe the 
assembly of 3-dimensional objects by joining multiple 2-dimensional objects, or layer-by-layer 
assembly. This technique allows for the rapid manipulation of design since there is no need for 
retooling of machines. Process parameters can quickly be changed providing more diverse products. 
Instead of a pharmaceutical company making drug formulations with two or three concentrations of 
API, a specific formulation can be made for each patient. Customize dosage and design of drug 
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release profiles for a specific purpose and person are two of the claims achievable through additive 
manufacturing. 37 
Most of the current additive manufacturing techniques for pharmaceuticals is based on a 
drop-on-demand production,38, 39 where material is added dropwise onto a substrate until a final 
formulation is achieved. These techniques provide highly controllable API deposition onto an edible 
substrate, and can be made compatible with solvent-based and melt-based systems. These systems 
often incorporate some type of on-line monitoring for quality-by-control purposes. An integral step 
of additive manufacturing will be the use of real-time monitoring for product control and quality.40 
The US FDA is encouraging consideration of several factor during development including, 
materials, design, printing, and post printing validation, printing characteristics, printing parameters, 
and physical and mechanical properties.41 Different techniques for additive manufacturing are 
desired to increase the applicability and scope of additive manufacturing. An ideal technique would 
allow for large scale production, control over the crystal form and morphology, and compatibility 
with a wide range of drugs.  
1.4 Meniscus-guided Coating for Additive Manufacturing 
Meniscus-guided coating is a technique previously used to tune molecular packing and 
crystalline thin film morphology of small molecules and polymers. In this technique a thin layer of 
solution is deposited on a substrate and crystallization occurs as the solution is deposited. 
Commonly used for small molecule organic semiconductors, meniscus-guided coating may also be a 
good technique for pharmaceutical small molecule deposition. Growth of thin films have been 
documented to trap or stabilize metastable polymorphs,42 grow with different crystal morphology43 
likely impacting the physiochemical properties of the material.  
In this work meniscus-guided coating was investigated as a possible technique for additive 
manufacturing of APIs. Pullulan, a biocompatible polymer, will be used as the substrate and 
crystalline films of aspirin and ellipticine, two model drugs, will be investigated. The focus of this 
work will be to understand how process parameters such as solution concentration and shear rate 
affect crystallization outcomes. Control of film morphology, thickness, and polymorph will be 
discussed. 
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Chapter 2 
X-ray Compatible Microfluidic Platforms
1
 
2.1 Introduction 
To determine the crystal structure of API’s with X-ray diffraction, high quality crystals need 
to be obtained. This can be challenging because a wide range of supersaturation levels need to be 
screened to obtain detailed phase behavior information, which can then guide crystallization of 
diffraction quality crystals.1 Diffraction quality crystals can be grown by supersaturating a solution 
until it reaches the labile zone (nucleation zone) where nuclei form, then reduction of the 
supersaturation level of the solution to the metastable zone (crystal growth zone) will ensure growth 
of the nuclei into crystals, without additional nuclei being formed.2, 3 In principle this sequence of 
steps can lead to monodisperse, diffraction quality crystals; however, precise control of 
supersaturation is not trivial.4, 5 Furthermore, the stochastic nature of the nucleation process often 
results in a broad crystal size distribution as well as poor control over the solid forms obtained.6 
Some of the aforementioned issues can be overcome by implementing advanced protocols 
to decouple crystal nucleation and growth leading to more narrow crystal size distribution and better 
control over the specific solid form obtained.7, 8 For example, the seeding approach, in which 
previously formed microcrystals are used to initiate crystal growth (thus eliminating the stochastic 
nucleation process), can be used to grow large and mono-disperse crystals.2 During initial screening, 
pharmaceuticals and proteins tend to crystallize as microcrystals, spherulites, fine needles, or poorly 
formed crystals. These crystalline solids can be micronized and then used as seeds in subsequent 
crystallization trials to enhance crystal quality. This process is reiterated until diffraction quality 
crystals are formed. The process of consistently introducing microseeds in a crystallization trial is 
challenging, although robots to automate this process have been used with some success. Still, 
obtaining single and isolated diffraction quality crystals remains a challenge. An inexpensive, high 
throughput technology that can simplify the seeding protocol and enable good control over seed 
1 
Part of this work has been published: E. M. Horstman*, S. Goyal*, A. Pawate, G. Lee, G. G. Z. Zhang, Y. Gong, 
and P. J. A. Kenis. “Crystallization Optimization in X-ray Compatible Microﬂuidic Platforms to Determine Structures 
of Pharmaceutical Solid Forms”. Crystal Growth & Design, 15(3), 1201-1209, 2015. *Contributed equally 
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transfer would be instrumental in the crystallization and structure determination of solid forms. 
Progress in microfluidics has resulted in the development of microfluidic platforms for 
pharmaceutical crystallization of different solid forms, such as polymorphs, salts, and cocrystals.9-16 
Utilization of microfluidic platforms allows for solid form screening at earlier stages of drug 
development when only very small quantities of APIs are available. For example, platforms based on 
droplets,13, 15 patterned surfaces,16 free interface diffusion,10, 12 antisolvent addition,9 temperature 
control,14 and evaporation11 have been employed for pharmaceutical crystallization. Some of the 
aforementioned platforms allow for crystal harvesting and subsequent analysis via traditional 
approaches17-19 and some allow for on-chip characterization which eliminates the need for manual 
crystal harvesting. 10, 11, 20-22 In prior work, the Kenis group developed microfluidic platforms for 
pharmaceutical solid form screening employing free interface diffusion, antisolvent addition, and 
solvent evaporation that allow for solid form identification via on-chip Raman spectroscopy.9-12 
Similarly, microfluidic platforms comprised of X-ray transparent materials have been use for 
crystallization screening and X-ray data collection for protein crystals on-chip.20-23 
Here, a microfluidic approach for pharmaceutical solid form screening that (1) enables 
crystallization optimization by crystal seeding, and (2) allows for on-chip X-ray data collection from 
crystals formed. The approach was validated using a model API, carbamazepine (CBZ) as well as a 
cocrystal carbamazepine-4-hydroxybenzoic acid (CBZ-4HBA). The chemical structure for these 
Figure 2.1. Chemical structures of carbamazepine and 4-hydroxybenzoic acid. 
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compounds can be found in Figure 2.1. 
2.2 Experimental 
2.2.1 Platform Design 
The 72-well microfluidic platform used here (Figure 2.2) is an adaptation of a previously 
reported design.11, 12 Briefly, each well was comprised of adjacent chambers for an API and 
microseed solution (Figure 2.2a). The dimensions of the adjacent chambers were varied to screen 
different volumetric ratios of the seed solutions and API solutions. Each well has a height of 50 µm, 
a width of 1 mm and a total length of 2 mm. The total volume of the wells was approximately 100-
nL. The ‘length’ of the API and microseed chambers were varied to achieve dilution on-chip in 
ratios of 2:1, 1:1 and 1:2, as schematically shown in a 3 × 3 array in Figure 2.2b. Varying the relative 
size of the chambers changes the concentration of seeds transferred between the chambers. In this 
design, the microchannels utilize a ‘zig-zag’ to connect adjacent wells reducing issues with dead 
volume and bubbles and ensuring faster and complete filling of the chambers (Figure 2.2c). This 
platform design was ideal for performing crystallization screening experiments because numerous 
conditions could be screened within one experiment without consuming large quantity of sample. 
Further description of platform fabrication and utilization can be found in Appedix A.1. 
2.2.2 Crystallization 
Saturated Solution. A saturated solution of the CBZ in acetonitrile (0.16M) was prepared for 
crystallization experiments. For cocrystal experiments, a 4HBA (cocrystal former) solution in 
acetonitrile (0.16 M) was prepared. 
Off-chip Crystallization. Seeds for on-chip seeding trails were obtained from crystallization of 
the CBZ and CBZ / HBA off-chip. A saturated solution of CBZ was allowed to evaporate in a glass 
vial covered with parafilm and a small hole poked in the top. The measured solvent evaporation rate 
was 6-24 µL/hr. The solvent was allowed to fully evaporate resulting in a deposition of CBZ crystals 
on the walls and bottom of the glass vial. The crystals were removed and powder X-ray diffraction 
(PXRD) data was collected from the off-chip sample and compared to published data to confirm 
the identity of the off-chip solids. To prepare seeds of the CBZ-4HBA cocrystal, an equal volume of 
CBZ and 4HBA in acetonitrile was dispensed into a glass vial and allowed to evaporate through the 
same procedure as described above. 
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Figure 2.2. (a) Cross sectional view of three microfluidic crystallization wells showing the layered 
assembly of the platform. Diffusional mixing occurs between adjacent chambers when the mixing 
valve (2) is actuated.  (b) Top view of a 3x3 array of microfluidic crystallization wells showing 
adjacent chambers and two sets of valves for introducing solutions and mixing solutions. (c1-6) 
Schematic demonstration of how to operate the platform. (c1) Empty platform; (c2) valve set 1 is 
actuated to start filling of the wells; (c3) microseed solution or API solution is loaded into the 
crystallization wells; (c4) crystallization wells are completely filled, after which valve set 1 is 
closed; (c5) valve set 2 is opened and diffusional mixing between the adjacent chambers begins; 
(c6) valve set 2 is closed and diffusional mixing within the microseed and API chambers. 
Seed Solution. Crystals were harvested from the off-chip crystallization experiments. First, 
approximately 1.5 mg of the API or cocrystal crystals grown off-chip were harvested from the glass 
vial and carefully placed in the glass tube of a tissue homogenizer, and 600 μL of saturated API 
solution was added to the glass vial, yielding a solution with an approximate seed concentration of 
2.5 mg/mL. The crystals were then pulverized using the homogenizer until no crystal agglomerates 
could be seen. The resulting seed stock solution was serially diluted with saturated drug solution 
with volumetric ratios of 1:2 (1.25 mg/mL), 1:5 (0.5 mg/mL), and 1:10 (0.25 mg/mL). Each 
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successive dilution contains fewer and fewer seeds. Seed stock solution preparation and off-chip 
dilutions are shown schematically in Figure 2.3. 
 
 
2.2.3 Characterization 
Optical Microscopy. Optical micrographs of crystals were taken with a Leica M205 C stereo 
microscope. The number of crystals, crystal quality (clarity, defects, single), and crystal number were 
noted to determine the effect of seed concentration on crystallization outcome. 
Powder X-ray Diffraction. Powder X-ray diffraction data was collected on a Rigaku Miniflex 600 
in the Bragg-Brentano geometry. The data was collected from 3° – 80° 2θ with 0.02° steps and a 
1.00 s detection time.  
On-chip X-ray Diffraction. X-ray data was collected on crystals while they still resided within 
the microfluidic platform. Typically, crystals are mounted on a loop, cryo-cooled, and rotated 180-
360° in the X-ray beam to collect a full data set. The typical data collection strategy would not work 
for our samples due to geometric constraints of the microfluidic platform. A strategy previously 
used for protein crystal data collection within a microfluidic platform was adapted to accommodate 
small molecule x-ray data collection on a microfluidic platform.20, 24 Data collection was performed at 
the synchrotron source at Argonne National Laboratory. The modified data collection strategy is as 
follows. First, the size of the microfluidic platform was reduced by cutting out a few wells. The 
Figure 2.3. (a) The identity of crystals grown off-chip were verified via powder X-ray diffraction. 
(b) The solid form crystals were crushed in a saturated CBZ solution to prepare a seed solution. 
(c) The seeding solutions are introduced on-chip along with CBZ solution (or premixed 
CBZ/4HBA solutions). Subsequently, the mixing valve is opened for 3 minutes to introduce 
seeds from the seed solution chamber to the adjacent chamber. 
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section of the platform was mounted on 
a standard magnetic goniometer with a 
metal tube and set screw to secure the 
platform. Data was collected at room 
temperature using 1° steps with a 1s 
exposure at an X-ray energy of 18 keV 
(λ = 0.689 Å, LS-CAT 21-ID-D). The 
geometry of the microfluidic platform 
made complete rotation of the chip (-
180° to 180°) for complete dataset 
collection challenging. Instead, small 
wedges of data (10-40° per crystal) were 
collected from a number of crystals. 
The frames were later merged together 
to form a complete dataset. This 
approach allowed for the collection of a 
complete dataset provided that the 
crystal orientation was random (not 
templated by the microfluidic platform). 
The employment of thin layers of 
PDMS and X-ray transparent COC 
maximizes transmission of X-rays through the chip materials, thereby enabling collection of high 
quality X-ray data from crystals formed on-chip. The characteristic scattering pattern of PDMS and 
COC observed in diffraction data collected on-chip occurs at relatively low angles of q-spacing or 
areas of low resolution diffraction (rings at 5.2Å for COC and at 7.5Å for PDMS) and does not 
affect the data collected at higher resolution. 
X-ray diffraction data was indexed, refined, integrated, and scaled using HKL2000 software. 
The resolution range of the data was established based on the resolution shell at which I/σ fell 
above 2.0. Subsequent processing of crystallography datasets was done using several programs 
including WinGx, Shelx, Shelxe, Shelxl, and Shelxs to identify the space group, generate the electron 
density maps, and generate the final crystal structure images. 
Figure 2.4. (a) The microfluidic chip mounted at 
the Argonne beam line (LS CAT 21-ID-D). (b) 
Example of diffraction data for CBZ-4HBA. The 
background from the chip material can be observed 
in the form of dark rings at low resolutions. (c1) 
Crystals of different compounds in individual wells: 
(c1) CBZ-4HBA, and (c2) CBZ. 
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Figure 2.5. Results of the on-chip seeding experiment for CBZ-4HBA. The variation in the 
number and size of crystals can be observed as a function of seed dilution ratio (blue box) and 
microseed to crystallization solution chamber ratio (red box). 
2.3 Results 
2.3.1 On-chip Seeding 
CBZ-4HBA. The cocrystal of CBZ-4HBA is known to have 3 polymorphic forms, 
designated as forms A-C. Two of the polymorphs are made up of a 1:1 ratio of CBZ : 4HBA (form 
A and form C), and the third polymorph is composed of a different ratio (1:X) of CBZ : 4HBA 
(form B).25 Form A is the most stable polymorphic form, with form C being metastable relative to 
form A at room temperature. In on-chip seeding experiments for CBZ-4HBA, Figure 2.5, fewer and 
larger crystals were observed upon increasing the dilution ratio from 1:2 to 1:10. This was expected 
since crystallization is primarily controlled by crystal growth of the cocrystals seeds. Similarly, when 
fewer cocrystal seeds were present (at higher dilution ratio) we saw a higher number of high quality 
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CBZ-4HBA CBZ 
empirical formula C15H12N2O, 
C7H6O3 
C15H12N2O 
formula weight 374.38 236.27 
temperature (K) 298 298 
wavelength (Å) 0.68875 0.68875 
crystal system monoclinic monoclinic 
space group P 21/c P 21/n 
a (Å) 7.112 7.542 
b (Å) 12.764 11.155 
c (Å) 20.288 13.919 
α (°) 90 90 
β (°) 92.143 92.885 
ϒ (°) 90 90 
volume (Å
3
) 1840.410 1169.500 
Z 4 4 
densitycalc (mg/m
3
) 1.351 1.342 
absorption coefficient (mm
-1
) 0.089 0.081 
θ range for data collection (°) 0.973 to 28.200 2.620 to 26.590 
data/restraints/parameters 5124/1/583 2538/1/422 
completeness to theta (%) 98.8 89.8 
goodness-of-fit of F
2
 0.983 1.077 
final T indices [I > 2σ(I)] R
1
 = 0.0540 
wR
2
 = 0.1512 
R
1
 = 0.0395 
wR
2
 = 0.1119 
 
crystals, Figure 2.5. Polymorph form A was predominantly observed when microseeds of the same 
polymorph were used in the experiments. The seeds were confirmed to be form A by comparing 
experimental PXRD with simulated powder patterns from the known crystal structures. These 
results imply that seeding not only aids in growing single, isolated crystals but it also aids 
crystallization of one particular polymorph or form of the cocrystal. Seeding drastically increased the 
number of crystals compared to the control, Figure 2.5, and variation in the well geometry helped to 
control the number and size of crystals generated. When the length of the seed chamber to the 
adjacent chamber was varied from 1:2 to 2:1 the size of the resulting crystals decreased while the 
number of crystals increased for all dilution ratios, Figure 2.5. 
CBZ. Four polymorphic forms of CBZ, designated as form I – form IV, have been 
reported.25 The most stable polymorph is form III, however the difference in energy from the most 
stable to the least stable polymorph is less than 0.7 kcal/mol.25 Crystallization control experiments 
on-chip resulted in a mixture of form II (needles) and form III (prisms) crystals. Employment of the 
seeding method directed the crystallization towards predominant formation of form III crystals. The 
seeds used in our experiment were polymorph form III confirmed with PXRD. In the control 
experiment, unit cell analysis of diffraction quality crystals was used to distinguish between crystal 
forms. Due to the presence of multiple solid forms, no on-chip diffraction data was collected from 
the control wells.  
2.3.2 Structure Determination  
 The data in this study was 
collected at room temperature using the 
method described Section 2.2.3 under 
On-chip X-ray Diffraction. The crystal 
structure of CBZ-4HBA and CBZ were 
solved to a resolution of about ~0.7 Å. 
The on-chip crystals were randomly 
oriented and data collected from 10-15 
crystals resulted in a completeness of 
99.7% for CBZ-4HBA and 89.4%. CBZ-
4HBA was found to have two CBZ and 
Figure 2.6. Asymmetric units of CBZ-4HBA and 
CBZ solved from diffraction data collected on-chip.  
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2 4HBA molecules in the asymmetric unit, and packs in a monoclinic unit cell. The solved crystal 
structure closely resembles the reported crystal structure. The crystal structure for CBZ was found 
to have two CBZ molecules in the asymmetric unit and pack in a monoclinic unit cell. The solved 
crystal structure closely resembles the form III crystal structure previously reported. Relevant 
crystallographic data can be found in Table 2.1.The crystal structure were compared to previously 
reported structures deposited in the Cambridge Crystal Structure Database. The reference codes for 
the reported structures are MOXVIF and CBMZPN02, for comparison with CBZ-4HBA and CBZ 
respectively. 
2.3.3 Advantage of Microfluidic Platform 
The microfluidic platform developed for crystallization optimization provides a simplified 
crystal seeding method for growth of diffraction quality crystals. Use of pneumatic valves allows 
precise metering of small solution volumes with ease. The design of the platform with varying 
volumetric ratios of microseed solution and adjacent solution allows a wide range of crystallization 
conditions to be screened without extensive manual experimental setup (solution preparation and 
pipetting). In addition to simple experimental set-up, the microfluidic platform provides greater 
control over solution mixing and solvent evaporation. Diffusional mixing between seed solution and 
crystallization solution allows the concentrations within each chamber to gradually change, 
enhancing the chances of the supersaturation level maintaining the crystal growth zone instead of  
traversing into the crystal nucleation zone, Figure 2.7. By incubating the platforms in a solvent vapor 
atmosphere, the rate of solvent evaporation is further reduced leading to better crystal growth. 
A key advantage of this microfluidic platform is the compatibility with solid form 
characterization methods (optical microscopy, Raman, and X-ray diffraction) eliminating the time 
consuming task of crystal harvesting followed by off-chip analysis of each crystal individually. In an 
on-chip experiment, identification of diffraction quality crystals with optical microscopy is relatively 
straightforward. With off-chip experiments, identification of single diffraction quality crystals among 
many poorly formed crystals can be challenging. In addition, thin crystals, often too fragile to be 
harvested, can be analysed on-chip. 
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Table 2.1. Crystallographic information for CBZ-4HBA and CBZ. 
  
 
CBZ-4HBA CBZ 
empirical formula C15H12N2O, 
C7H6O3 
C15H12N2O 
formula weight 374.38 236.27 
temperature (K) 298 298 
wavelength (Å) 0.68875 0.68875 
crystal system monoclinic monoclinic 
space group P 21/c P 21/n 
a (Å) 7.112 7.542 
b (Å) 12.764 11.155 
c (Å) 20.288 13.919 
α (°) 90 90 
β (°) 92.143 92.885 
ϒ (°) 90 90 
volume (Å
3
) 1840.410 1169.500 
Z 4 4 
densitycalc (mg/m
3
) 1.351 1.342 
absorption coefficient (mm
-1
) 0.089 0.081 
θ range for data collection (°) 0.973 to 28.200 2.620 to 26.590 
data/restraints/parameters 5124/1/583 2538/1/422 
completeness to theta (%) 98.8 89.8 
goodness-of-fit of F
2
 0.983 1.077 
final T indices [I > 2σ(I)] R
1
 = 0.0540 
wR
2
 = 0.1512 
R
1
 = 0.0395 
wR
2
 = 0.1119 
 
Comparing the results of off-chip seeding experiments (in 1mL glass vials) for CBZ and 
CBZ / 4HBA with those of on-chip seeding, revealed that the outcomes of on-chip experiments 
typically are better in terms of the quality of the crystals obtained, the ease by which they can be 
found within a well, and the number of experiments leading to crystals. These outcomes of on-chip 
experiments are the result of better control over solvent evaporation and the addition of seeds 
(often too many seeds are added in an off-chip experiments, leading to showers of crystals), as well 
as better control over mixing of the seed solution with the crystallization solution.  
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2.4 Conclusion 
In this chapter, a microfluidic approach to optimize crystallization and subsequently 
determined structures of pharmaceutical solid forms via on-chip X-ray analysis was reported. 
Specifically, a 72-well (8 x 9) array-based microfluidic platform was used to screen unique seeding 
conditions of CBZ and CBZ-4HBA by varying the volumetric ratio of the microseed solution to 
crystallization solution. Screening microseed dilutions along rows helped determine optimized 
conditions for crystallization of numerous crystals that are large enough for X-ray diffraction. In the 
case of carbamazepine, the seeding approach also aided in producing crystals of a specific solid form 
(form III) over a mixture of forms II and III. The platform was engineered to enable X-ray data 
collection on-chip by minimizing materials thickness which maximizes the transmission of X-rays. 
Data was collected on different crystals and later merged together to form a complete dataset and 
resulted in the determination of the structure of pharmaceutical solid forms. Key attractive features 
of these platforms are easy handling and simplified seeding while using small quantities of CBZ 
(about 5 microgram/well), and compatibility with X-ray diffraction. Ease of operation, requiring 
only a vacuum source, enables immediate application of these chips in laboratories for solid form 
crystallization. 
Going forward, better control over crystallization outcomes would be expected if 
temperature control was integrated with the microfluidic platforms. A wider range of 
Figure 2.7 Comparison of crystallization results with (seed) and without seeding (control). All 
images are of a 1:1 microseed to crystallization solution chamber ratio. 
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supersaturation conditions could be screened and experiments could be conducted in the metastable 
zone (growth zone) to maximize the advantages of seeding. One can also foresee using this platform 
to study the effects of additives (polymers, surfactants, and antisolvents) on crystal morphology, 
polymorphism, and amorphous form stabilization.  
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Chapter 3 
Microfluidic Platforms for Solid Form Discover
1
 
3.1 Introduction 
In the pharmaceutical industry BCS Class II drugs are reported to make up about 60-90% of 
drugs in the pipeline.1-3 These drugs are characterized by low solubility across physiological pH 
range. Crystallization of these parent compounds with cocrystal formers (CCFs) provides a way to 
enhance the physiochemical properties of the solid form and improve their performance.4-8 
Thousands of food ingredients and additives have been recognized by the U.S. Food and Drug 
Administration as being safe for human consumption and a majority of this list may be acceptable 
for crystal engineering of pharmaceutical solids.9 Since predictive cocrystal formation has not been 
fully developed, high throughput cocrystal screens with a large number of CCFs are often used to 
discover novel solid forms of a parent compound. Many techniques have been developed for 
cocrystal screening including solution based (e.g. evaporation, solvent diffusion, anti-solvent 
addition) and mechanochemical based (e.g., grinding, twin screw extrusion) approaches.10-13 
Although high throughput cocrystal screens can be effective at generating novel cocrystals, 
the success of finding a cocrystal often depends on the screening method chosen.14 Deeper 
understanding of cocrystal formation is needed to aid the more rational design of cocrystal screening 
experiments. For example, MacGillivray et al. has examined cocrystals of theophylline and caffeine to 
characterize intermolecular and intramolecular synthons.10, 15, 16 This work also provided a systematic 
study to determine synthon hierarchies in molecules with multiple potential hydrogen bonding sites. 
Additionally, researchers at times analyze the several hundred thousand crystal structures of organic 
compounds available in the Cambridge Crystal Structure Database (CCSD), to help predict possible 
new cocrystals between CCFs and target parent compounds, based on hydrogen bond lengths and 
angles observed in previously reported structures.17 Despite these efforts, current design of cocrystal 
screens typically incorporates minimal rational input, resulting in low success rates in most current 
1 
Part of this work has been published: E. M. Horstman, J. A. Bertke, E. H. Kim, L. C. Gonzalez, G. G. Z. Zhang, Y. 
Gong, and P. J. A. Kenis. “Crystallization and Characterization of Cocrystals of Piroxicam and 2,5-
Dihydroxybenzoic Acid”. CrystEngComm, (17), 5299-5306, 2015; and E. M. Horstman, J. A. Bertke, T. J. Woods, 
and P. J. A. Kenis. “Crystal structure of a 2:1 piroxicam:gentisic acid cocrystal featuring neutral and zwitterionic 
piroxicam molecules”. Acta Crystallographia E. (E72), 1714-1717, 2016. 
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cocrystal screening efforts.  
Developing a deeper understanding of cocrystallization also relies on the ability to obtain the 
structure of the solid forms obtained. Many cocrystal screens, however, do not result in the 
formation of diffraction quality crystals. In those cases, bulk characterization methods such as 
powder X-ray diffraction (PXRD) or Raman spectroscopy are used to differentiate among starting 
materials, cocrystals, and cocrystal polymorphs. Knowing the crystal structure of the cocrystal is the 
only way to unequivocally identify what solid form has been crystallized. In the case of AMG 517, 
the API surprisingly cocrystallized with sorbic acid (present in only trace quantities) in the final 
formulation. The cocrystal of AMG 517 and sorbic acid drastically changed the physiochemical 
properties including increased exposures following an oral dosing to rats. 18 This incident highlights 
the challenges in predicting solid formation and underscores the importance of solid form screening 
during drug development. 
Several microfluidic approaches have been investigated as a way to study formation of 
pharmaceutical solid forms, enabling the screening of more conditions with small amounts of 
material.19-25 For example, in prior work we have demonstrated the use of microfluidic platforms to 
screen for cocrystals by diffusional mixing of an API solution and a CCF solution in adjacent 
compartments,19, 26, 27 at times in combination with solvent evaporation.28, 29 
Here we investigate cocrystals of piroxicam (PRX) and 2,5-dihydroxybenzoic acid (HBA), 
Figure 3.1. PRX is a non-steroidal anti-inflammatory BCS Class II drug. Three cocrystals of PRX 
and HBA have been previously reported.14 All three solid forms were obtained by solution mediated 
phase transformation and characterized via Raman spectroscopy and PXRD. In this work, a simple 
Figure 3.1. Chemical structures of piroxicam and 2,5-dihydroxybenzoic acid. 
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microfluidic platform consisting of arrays of single wells was used to screen for solid forms of PRX 
and HBA and identify crystallization conditions to grow diffraction quality crystals. This platform 
simulates the experimental conditions of a 96 well platform, while utilizing less volume of sample 
per condition screened and providing more control over the rate of solvent evaporation. We 
discovered several solid forms of PRX and HBA, two being cocrystals that had not been reported 
and another being a cocrystal that incorporates an impurity into its structure forming a solvated 
cocrystal. The aforementioned solid forms were characterized further via thermogravimetric analysis 
(TGA), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC). 
3.2 Experimental 
3.2.1 Platform Design 
The crystallization platform used in this study is composed of a 6 x 6 micro-well array and 
one set of valves to allow fluidic routing, Figure 3.2. Each micro well is about 1250 µm x 1500 µm x 
60 µm and houses approximately 110 nL of solution. The platform fabrication and operation is 
detailed in the Appendix A1.19, 28 Briefly, the platform is comprised of a thin poly-dimethylsiloxane 
(PDMS) control layer to control fluid routing and a fluid layer to provide fluid storage. The PDMS 
layers are sandwiched between a cyclic olefin copolymer (COC) support layer and a substrate layer. 
The COC layers provide physical rigidity and reduced solvent loss. The support, control, and fluid 
layers were irreversibly bound together, then this assembly was reversibly bound to the substrate 
Figure 3.2. (a) A 3x3 array of the microfluidic platform showing that the platform can be peeled 
apart to harvest crystals grown on-chip. (b) Magnified view of a single well as well as a cross 
sectional view of the chip to highlight the position of the valves, and the ‘zig-zag’ design used to 
decrease trapping of bubbles when filling the chip. 
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layer to allow for easy access to the solids crystallized on-chip by peeling apart the chip, Figure 3.2.  
3.2.2 Crystallization Trials 
Single Crystal Growth. Single crystals of PRX-HBA were grown on-chip from an acetonitrile 
solution. PRX was added to acetonitrile until saturation (~0.034M), and then an equimolar ratio of 
HBA was added to form a crystallization solution. The PRX and HBA crystallization solution was 
introduced on-chip. After filling, the chip was placed inside a Petri dish and sealed with Parafilm. 
After complete solvent evaporation (1 day), PRX-HBA crystals were observed on-chip via optical 
microscopy. Initially, the crystals were characterized on-chip using Raman spectroscopy; then, 
crystals were harvested from the chip for structure determination using X-ray diffraction. 
Single crystals of PRX-HBA-ACT 2PRX- HBA were grown on-chip from an acetonitrile 
solution. PRX was added to acetonitrile until saturation (~0.034M), then a 1.5 molar ratio of HBA 
was added to form a crystallization solution.  The PRX and HBA crystallization solution was 
introduced on-chip. After filling, the chip was placed inside a Petri dish and sealed with Parafilm. 
After complete solvent evaporation (1 day), the PRX-HBA-ACT crystals were observed on-chip. 
Only several 2PRX-HBA crystals were observed. The PRX-HBA-ACT and 2PRX-HBA crystals 
have different crystal habits and are are easily distinguished with optical microscopy. The solid forms 
were characterized with on-chip Raman spectroscopy. The Raman spectra of PRX-HBA-ACT 
matched previously reported spectra.14 Crystals of both forms were harvested from the chip for 
structure determination. 
Bulk Crystallization. Equimolar ratios of PRX and HBA were slurried in acetonitrile for 12 
hours, to obtain gram scale quantities of PRX-HBA. The slurry was filtered to isolate the solids and 
the solids were allowed to dry. Bulk PRX-HBA-ACT cocrystal was crystallized by slurrying 
equimolar ratios of PRX and HBA in acetonitrile/acetone mixture (v/v = 2/1) for 12 hours. Excess 
acetone was added to the slurry to ensure complete conversion of the PRX-HBA-ACT cocrystal. 
The slurry was then filtered to isolate the solids and the solids were allowed to dry. 
3.2.3 Characterization 
Optical Microscopy. Optical micrographs of crystals were taken with a Leica M205 C stereo 
microscope to observe crystal habit and crystal color. 
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Raman Spectroscopy. On-chip Raman spectra was collected using a Renishaw mircoPL/Raman 
microscope equipped with a 785 nm excitation source and a Renishaw NIR 100 mW diode laser. 
Data was collected in the range of 600−1800 cm−1 at a spectral resolution of ∼0.5 cm−1 at 1800 
gratings/mm. Spectra were obtained over a 10 s exposure and averaged over 2 accumulations. 
X-ray Diffraction. Single crystal X-ray diffraction data was collected on a Bruker D8 Venture 
equipped with a four-circle kappa diffractometer and Photon 100 detector. An Iμs microfocus Cu 
source supplied the multi-mirror monochromated incident beam. A combination of Phi and Omega 
scans were used to collect the necessary data. A single crystal was picked and mounted on a 0.3mm 
loop using paratone oil. The samples were cooled to 100 K or 222K (PRX-HBA or PRX-HBA-
ACT, respectively) in a nitrogen supplied Oxford 700 Cryostream. Data was integrated using SAINT 
and absorption corrected using SAINT/SADABS v2012/1 or SAINT/SADABS v2014/2. The final 
structure was solved using SHELX-2013-4 or SHELX-2014-3. 
Powder X-ray Diffraction. Powder X-ray diffraction data was collected on a Rigaku Miniflex 600 
in the Bragg-Brentano geometry. The data was collected from 3° – 80° 2θ with 0.02° steps and a 
1.00 s detection time. 
Thermogravimetric Analysis. Mass loss data was measured with a TA Q50. Approximately 10 mg 
of material was measured and placed in an alumina cup and loaded on a platinum pan. Samples were 
heated from 25°C to 250°C at 5 °C /min. Dry nitrogen was used as a purge gas with a balance purge 
flow rate of 40 mL/min and sample purge flow rate of 60 mL/min. 
Differential Scanning Calorimetry. Cocrystals thermograms were obtained using a TA Q2000. 
Approximately 5 mg of material was measured and crimped into a small aluminium pan. Samples 
were heated from 25 °C to 225 °C at 5 °C /min. An empty sealed aluminium pan was used as a 
reference. Dry nitrogen was used as a purge gas at a flow rate of 20 mL/min. 
3.3 Results 
3.3.1 Cocrystal Screen 
Crystallization of PRX-HBA cocrystal was first carried out on-chip at 1:1 molar ratio in six 
solvents (mixtures), i.e. methanol, trifluoroethanol, acetonitrile, methanol/trifluoroethanol (v/v = 
1/1), methanol/acetonitrile (v/v = 1/1), and trifluoroethanol/acetonitrile (v/v = 1/1). Thin needle-
like crystals were observed in all solvents (mixtures) except in acetonitrile. The crystals collected in 
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the three solvent mixtures were too small to give acceptable Raman scattering. Raman spectra of the 
needle-like crystals grown in methanol and trifluoroethanol were collected and found to matched 
with that of Form 18B1 previously reported by Childs et al..14  Crystallization of PRX and HBA 
(PRX-HBA) in acetonitrile led to large prismatic crystals (Figure 3.3a) with an unique Raman spectra 
that had not been reported (Figure 3.3). 
On-chip crystallization of PRX and HBA was then repeated in acetonitrile with a molar ratio 
of 1:1.5 and 1:2, respectively, to determine the impact of HBA concentration on the solid form. At 
both conditions, crystals collected on-chip presented two different morphologies, i.e. prism and 
plate, with more plate-like crystals at higher HBA concentrations. The Raman spectra of both 
crystals were collected on-chip. The plate-like crystals had the same Raman spectra as that of Form 
18C as previously reported by Childs et al. (Figure 3c).14 Several of the plate-like crystals had a 
different morphology and an unique Raman spectra that had not been previously reported. The 
prismatic crystals gave the same Raman spectra as the crystal identified in acetonitrile with 
PRX/HBA ratio of 1:1. 
3.3.2 Structure Determination 
Single crystal X-ray diffraction was used to determine the crystal structure for the three solid 
forms identified in the crystallization screen. The three solid forms were found to be a 1:1 molar 
ratio of PRX:HBA, a 1:1:1 molar ratio of PRX:HBA:ACT, and a 2:1 molar ratio of PRX:HBA. 
Crystallographic data is 
summarized in Table 3.1. 
The data collection 
for the PRX-HBA-ACT 
crystal proved to be 
challenging since the unit 
cell of the cocrystal changed 
with temperature. The first 
data collection was carried 
out at -200 °C, and although 
the diffraction data was not 
high enough quality to 
Figure 3.3. Images of (a) PRX-HBA ,(b) PRX-HBA (2:1) 
and (c) PRX-HBA-ACT grown in acetonitrile and their 
corresponding on-chip Raman spectra.  
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resolve the crystal structure, the unit cell was determined to be triclinic. To facilitate single crystal 
data collection, crystallization was repeated off-chip with molar ratio of PXR/HBA = 1:1.5. A larger 
crystal with the same morphology (plate-like) was collected and tested using single crystal x-ray 
diffraction at -200 °C. The data suggested the same unit cell (triclinic) but again, did not give a 
reliable structure. Data collection was repeated after bringing the same crystal back to room 
temperature. Optical inspection of the crystal showed signs of crystal degradation. However, a fresh 
Table 3.1. Crystallographic information for all solid forms. 
  
 
PRX-HBA  PRX-2HBA  PRX-HBA-ACT 
empirical formula C
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13
N
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O
4
S,  
C7H6O4, C3H6O 
formula weight 485.46 816.80 543.54 
temperature (K) 100 105 222 
wavelength (Å) 1.54178 1.54178 1.54178 
crystal system monoclinic triclinic monoclinic 
space group P 2
1
/c P ͞͞͞͞͞͞͞͞͞ ͞͞͞1 P 21/n 
a (Å) 14.243 8.788 6.839 
b (Å) 13.561 13.406 22.397 
c (Å) 11.744 15.268 16.322 
α (°) 90 80.466 90 
β (°) 112.525 85.433 98.7101 
ϒ (°) 90 78.460 90 
volume (Å
3
) 2090.03 1753.48 2471.27 
Z 4 2 4 
densitycalc (mg/m
3
) 1.543 1.547 1.461 
absorption coefficient (mm
-1
) 1.897 2.050 1.698 
θ range for data collection (°) 4.68 to 68.20 2.938 to 68.252 3.38 to 68.33 
data/restraints/parameters 3777/0/322 6416/374/637 4419/150/400 
completeness to theta (%) 98.6 99.8 97.2 
goodness-of-fit of F
2
 1.022 1.110 1.195 
final T indices [I > 2σ(I)] R
1
 = 0.0357 
wR
2
 = 0.0800 
R
1
 = 0.0334 
wR
2
 = 0.0836 
R
1
 = 0.0662 
wR
2
 = 0.1721 
CCDC 1049026  1049025 
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crystal with the plate-like morphology collected from the same crystallization batch was found to 
have a monoclinic unit cell at room temperature. Following this observation, x-ray diffraction data 
of the monoclinic crystal was collected again at -50 °C to reduce the thermal motion. A full data set 
was collected and the structure of the crystal was successfully solved.  
Acetone incorporation in the crystal structure was a surprise since acetone was not used in 
crystallization. The acetone is believed to be introduced as an impurity with HBA. This may be an 
excellent example on the impact of trace amount of impurity on the result of crystallization. To 
confirm the source of acetone further experiments were performed. Repeating the previously 
mentioned experiments using a different batch of acetonitrile yielded the same outcome, namely that 
the PRX-HBA-ACT cocrystal was observed in the experiments with a molar ratio of PRX/HBA = 
1:1.5 and 1:2. Since the acetone was believed to be present in the HBA, the HBA was heat-treated at 
100 °C for 3 hours, presumably removing any remaining acetone. When crystallization experiments 
were repeated using this heat-treated HBA, only PRX-HBA cocrystals were obtained, strongly 
suggesting that the acetone indeed was an impurity in the HBA. 
3.3.3 Crystal Structure Analysis 
PRX-HBA. This cocrystal grows in the monoclinic space group P21/c with one PRX and 
one HBA molecule in the asymmetric unit. Hydrogen bonding occurs between the pyridine and 
amide nitrogen atoms of PRX and the carboxylic acid of HBA. The hydroxy substituent in the 5- 
Figure 3.4. (a) Asymmetric unit of PRX-HBA shown as a 50% ellipsoid plot featuring one PRX 
molecule in a neutral configuration hydrogen bonded to a HBA molecule. (b) Orange dotted line 
show hydrogen bonding intramolecular and intermolecular interactions. 
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position on the HBA in the PRX:HBA cocrystal is hydrogen bonded to the hydroxyl substituent in 
the 2-position of a neighboring HBA. All hydrogen bonding occurs in one plane creating a 1-D 
wavy structure (Figure 3.4b). 
PRX-HBA-ACT. This solvated cocrystal also crystallizes in the monoclinic space group 
P21/c with one PRX, HBA, and ACT molecule in the asymmetric unit. Hydrogen bonding occurs 
Figure 3.6. (a) Asymmetric unit of PRX-2HBA shown as a 50% ellipsoid plot featuring one PRX 
molecule in a neutral configuration hydrogen bonded to a HBA molecule and one PRX molecule 
in the zwitterionic configuration. The HBA has whole molecule disorder with the primary 
position having occupancy of 0.809 and the secondary position having an occupancy of 0.191(b) 
Orange dotted line show hydrogen bonding intramolecular of the PRX neutral configuration and 
intermolecular interactions. 
Figure 3.5. (a) Asymmetric unit of PRX-HBA-ACT shown as a 35% ellipsoid plot featuring one 
PRX molecule in a neutral configuration hydrogen bonded to a HBA molecule which is hydrogen 
bonded to the ACT molecule. Data was collected at 222K which may be the reason the thermal 
ellipsoids are larger compared to the other two structures. (b) Orange dotted line show hydrogen 
bonding intramolecular and intermolecular interactions. 
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between the pyridine and amide nitrogen atoms of PRX and the carboxylic acid of HBA. The 
hydroxyl on the 5 position on the HBA is hydrogen bonded to the carbonyl oxygen in ACT. The 
ACT molecules are arranged along the a-axis, which is evident when looking at a stack of several 
unit cells of this crystal structure along this axis (Figure 3.4d). This arrangement possibly allows the 
ACT molecules to escape from the crystal structure when heated (experiment described below) 
without interrupting the hydrogen bonding between PRX and HBA.  
PRX-2HBA. The cocrystal contains a 2:1 ratio of PRX to HBA. Hydrogen bonding between 
the PRX and HBA forms layers in approximately the ab plane. The asymmetric unit of this cocrystal 
consists of two PRX molecules and one HBA molecule, with all atoms residing on general positions. 
The PRX molecules exhibit two different conformations in the crystal structure. In one 
conformation intramolecular hydrogen bonding exists between the amide oxygen atom and the 
hydroxide proton. Free rotation about the C—C bond allows a second zwitterionic conformation in 
which intramolecular hydrogen bonds exist between the amine proton and the ketone oxygen atom. 
An additional intramolecular hydrogen bond exists between the pyridinium proton and the amide 
oxygen atom. The HBA molecule is disordered over two positions rotated by approximately 180° in 
the plane of the aromatic ring with site occupancies of 0.809:0.191. The major orientation 
participates in intramolecular hydrogen bonding between the hydroxide substituent of the benzene 
ring and the oxygen atom of the carboxylic acid. The major orientation also participates in 
intermolecular hydrogen bonding. The minor orientation of the HBA molecule also displays 
intramolecular hydrogen bonding between the hydroxide substituent and the oxygen atom of the 
carboxylic acid but does not participate in intermolecular hydrogen bonding. Intermolecular 
hydrogen bonds between the PRX and HBA form hexameric units that propagate along the a-axis. 
These units pack into layers in the ab plane; the layers stack along the c-axis. 
3.3.4 Thermal Characterization 
A slurry method (see Experimental section) was used to obtain gram-scale quantities of 
PRX-HBA and PRX-HBA-ACT for thermal characterization. Raman spectroscopy was used to 
confirm the identity the slurried products. 
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Thermogravimetric Analysis (TGA). 
Thermogravimetric analysis was used to 
determine the temperature at which 
significant weight loss is observed, Figure 
3.7. Heated at 5 °C/min, solids of the 
starting materials PRX and HBA, and of the 
PRX-HBA cocrystal remained thermally 
stable until 200 °C, at which temperature the 
solids degraded. No mass loss was detectable 
due to acetone desolvation from the HBA, 
possibly due to detection limits of the 
instrument. The solid of PRX-HBA-ACT 
lost ~10.4% of its weight at 80 °C, 
presumably due to the loss of acetone from 
its lattice. This mass loss is in close 
agreement with the theoretical value of 
10.7%. PRX-HAB-ACT degraded at 200 °C when heated further. 
Powder X-ray Diffraction (PXRD). PRX-HBA-ACT solids were held at 100 °C for 1 hour and 
at room temperature for 1 month to evaluate the physical stability of the solid form. Complete 
desolvation of acetone is expected in the heat treated sample based on the TGA data. The heat 
treated sample was cooled to room temperature and PXRD data was collected for all the samples, 
Figure 3.8. The heat treated sample was compared to the PRX-HBA and PRX-HBA-ACT starting 
materials. The spectra for the heat treated cocrystal solvate correspond exactly to the peak positions 
observed for PRX-HBA. The heated samples show slightly broader peaks when compared to PRX-
HBA indicating that the heated samples have a smaller crystal size. Additionally, peak intensities of 
the heated samples do not directly correspond to the PRX-HBA, possibly due to preferred 
orientation of the heated samples. Comparison of these patterns with those of the non-solvated 
cocrystal PRX-HBA, suggests that the solid of PRX-HBA-ACT converts to the non-solvated 
cocrystal at elevated temperature. The PRX-HBA-ACT sample held at room temperature for 1 
month showed similar spectra to the starting material showing that the acetone within the structure 
will not leave the material under standard conditions. 
Figure 3.7. Thermogravimetric analysis 
data showing a 10.4% mass loss in PRX-
HBA-ACT from desolvation of acetone 
beginning at 80 °C. 
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Differential Scanning Calorimetry (DSC). The thermal events of the cocrystals and each of their 
components were recorded while heated to 250 °C, Figure 3.9. Solids of PRX-HBA exhibited a 
sharp melting endotherm at 194 °C followed by a weaker endothermic peak at 202 °C. These peaks 
are tentatively attributed to sublimation of HBA, which shows peaks at 202 °C and 206 °C, or 
melting of PRX, 201 °C, that partially crystallized after melting of the cocrystal. Solids of PRX-
HBA-ACT showed a broad endothermic peak at beginning at 65 °C and continuing to 104 °C likely 
due to desolvation of the cocrystal. The desolvated cocrystal melts at 194 °C followed by a weaker 
endothermic peak at 202 °C. The two cocrystals had the same melting temperatures and profiles 
suggesting that the solvate may have partially converted to the non-solvated cocrystal upon heating.  
3.4 Conclusion 
In this work, a cocrystal screen of PRX and HBA was used as a model system to investigate 
cocrystalliztion of BCS Class II compounds. Class II compounds make up the majority of the drugs 
currently in the pharmaceutical pipeline and increasing the solubility of the API, for example via 
Figure 3.9. Differential scanning calorimeter 
data for PRX, HBA, PRX-HBA, and PRX-
HBA-ACT. A small bump in the graph can be 
seen in the PRX-HBA-ACT graph near 105 °C 
from the desolvation of acetone.  Both 
cocrystals have a lower melting point than the 
melting point of PRX and the sublimation 
temperature of HBA. 
Figure 3.8. Powder X-ray diffraction data 
from the PRX-HBA and PRX-HBA-ACT 
compared with a PRX_HBA-ACT sample 
that was held at 100 °C for 1 hour. As PRX-
HBA-ACT loses ACT, the powder patterns 
begin to resemble that of PRX-HBA. 
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cocrystalliztion, could ultimately determine the fate of the API. A simple microfluidic platform was 
developed to perform a cocrystal screen by solution mediated phase transformation through solvent 
evaporation. The platform is comprised of a 6 x 6 array of single micro-wells that are isolated with 
normally closed valves to replicate the experimental conditions of a 96 well plate. The shallow wells 
(~60 μm) and transparent chip materials allow for easy detection of solid forms on-chip as well as 
subsequent characterization of these solid forms with Raman spectroscopy. The platform is easy to 
manufacture and operate and only requires a vacuum source and pipette for filling. 
The crystallization screen yielded high quality crystals of three solid forms: a PRX-HBA 
cocrystal, a PRX-HBA-ACT solvated cocrystal and a 2PRX-HBA cocrystal. Acetone incorporation 
into one of the solid forms was a surprising find, and was attributed to an impurity in the HBA 
starting material. Bulk quantities of PRX-HBA and PRX-HBA-ACT were synthesized for physical 
characterization via TGA, PXRD, and DSC. With TGA the only observed noticeable mass loss from 
PRX-HBA-ACT, 10.4 wt%, attributed to desolvation of acetone. Investigation of the stability of 
PRX-HBA-ACT revealed that this solid form is stable at 25 °C. Upon increasing the temperature to 
100 °C the PRX-HBA-ACT desolvated resulting in a PXRD pattern that is similar to the spectra 
obtained for PRX-HBA. In this work we demonstrated the utility of microfluidics in pharmaceutical 
drug discovery, in particular with respect to solid form screening and subsequent solid form 
characterization. The results presented here also underscore the importance of crystal structure 
determination to confirm solid form. 
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Chapter 4 
Biomimetic Crystallization and Solid Form Screen
1
 
4.1 Introduction 
Abnormal morphology of crystals has been a subject of significant study over the last 
century.1-6 Particularly, crystalline growth and distribution within living organisms such as cells, 
tissues or even clinically in humans has allowed us to understand how solid-state crystal chemistry 
can modulate their biological and biophysical environments.7-12 Specifically, the interaction of 
crystalline matter with cells such as macrophages within clinical microenvironments has garnered 
much attention.13-15 Macrophages (Mφs) are critical self-nonself recognizing immune cells capable of 
maintaining mammalian homeostasis and resolving 
inflammatory conditions responsible for many diseases. 
Concurrently, Mφs are cellular “vacuum cleaners” eliminating 
foreign matter, typically referred to as xenobiotics. Such 
elimination may also be preceded by massive bioaccumulation, 
self-assembly and intracellular crystallization of sequestered 
foreign molecular agents such as clofazimine (CFZ, Figure 
4.1), a red-pigmented, anti-inflammatory, FDA-approved drug 
molecule.16, 17 Specifically, CFZ accumulates within Mφs upon 
prolonged oral dosage in humans18-21 and rodent models13, 22-25 
(protocol in Appendix A.2) to form biocrystals containing 
clofazimine hydrochloride (CFZ-HCl) crystalline domains.26 
Mechanical properties of crystals (moduli, plasticity, 
elasticity) are known to be dependent on the atoms, ions or molecules forming the crystals and the 
interactions between these particles (molecular packing and intramolecular bonding).27-31 Further, 
recent work has explored the relationship between elasticity in organic crystals and their molecular 
and structural properties. Ghosh and Reddy observed an elastic organic crystal of caffeine-4-chloro-
Figure 4.1. Chemical structures 
clofazimine. 
1 
Part of this work has been or will be  published: E. M. Horstman*, R. K Keswani*, B. A. Grey, P. M. Rzeczycki, V. 
Lalone, J. A. Bertke, P. J. A. Kenis, and G. R. Rosania. “Elasticity in Macrophage-Synthesized Biocrystals”. 
Angew. Chem. Int. Ed., (56), 1815-1819, 2017; and E. M. Horstman, R. K Keswani J. A. Bertke, G. R. Rosania, 
and P. J. A. Kenis. “Biomimetic Polymorph of Clofazimine Hydrochloride”. To be submitted 
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3-nitrobenzoic acid cocrystal with weak and dispersive C-H···π interactions in three nearly 
perpendicular directions, suggesting that elastic deformation is due to isotropic molecular packing.28, 
30 Subsequently, Ghosh et al. studied n-benzylidene anilines and describes design rules for elastic 
organic crystals.27-29 According to this study, elastic crystals should have (1) multi-directional weak 
dispersive bonds that can be easily broken to dissipate energy as the crystal is bending and that can 
be easily formed when no force is applied and (2) corrugated packing along a crystallographic face to 
prevent long range dislocation within the crystal.27-29 In their studies, when crystals did not align with 
these design rules the crystals did not demonstrate elastic behavior. As such, we explored if elasticity 
and curvature of biocrystals could be explained via these design parameters. 
Additionally, in the prior work by Ghosh et al., they noted that polymorphs of the elastic 
organic crystals were not observed despite repeated trial.27 An additional aim of this work was to 
grow polymorphs of the biomimetic CFZ-HCl crystal with the hypothesis that a non-biomimetic 
CFZ-HCl crystal would be characterized by the reduced presence or absence of the weak, non-
covalent interactions setup by the salt chloride ions. 
4.2 Experimental 
Information on biocrystal preparation can be found in Appendix A.2. 
4.2.1 Crystallization 
Solution Preparation. Crystallization solutions were made by dissolving CFZ in methanol or 
acetone to a concentration of 2 mM (or 8 mM). When the CFZ was dissolved a small amount of 12 
M HCl was added to the solution to create a 0.1 M HCl concentration. After the HCl is added the 
solution will change color, typically from a bright red to a dark red or purple depending on the 
solvent. This crystallization solution was allowed to evaporate in a glass vial and in a microfluidic 
device. Glass vial crystallization: Approximately 500 μL of the crystallization solution was dispensed 
into a 20 mL glass vial and allowed to evaporate very slowly. Once crystals were observed, the lid of 
the vial was tightened to prevent further solvent evaporation. Crystals are harvested with a metal 
spatula and mounted for XRD. Microfluidic crystallization: Approximately 30 μL of crystallization 
solution was used to fill a 6 x 6 array of single micro-wells (volume ~100nL). Once the device was 
filled, the device was placed in a petri dish and the petri dish was sealed with parafilm to reduce the 
rate of solvent evaporation. The solvent was allowed to completely evaporate (typically takes 1 day). 
Crystals were harvested by cutting the microfluidic device and peeling the device apart. Crystals are 
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mounted on a traditional magnetic loop for XRD. Detailed descriptions of microfluidic device 
fabrication and utilization have been previously reported in Chapter 3: Experimental Section and 
Appendix A.1. 
Crystallization of Bulk CFZ-HCl polymorph I. Bulk CFZ-HCl polymorph I crystals were grown 
by adding HCl to a 2mM CFZ in methanol solution until the HCl concentration was 0.1M. After the 
solution sat for 5 minutes, water is added to the solution to double the solution volume. Within 
minutes, thin dark red crystals were observed. To grow diffraction quality crystals of CFZ-HCl, 
2mM CFZ was dissolved in benzene and 0.1M HCl was added to the solution. The solution was 
allowed to slowly evaporate and red, rectangular plate-like crystals were observed. 
4.2.2 Characterization 
Microscopy of Synthetic Crystals. Optical micrographs of crystals were taken with a Leica M205 C 
stereo microscope. 
Powder X-ray Diffraction. Powder diffraction data of isolated biocrystals was carried out as 
published26 with Bruker D8 Advance: Cu Kα radiation (λ = 1.5406 Å), tube voltage = 40 kV, and 
tube current = 40 mA. Data were collected at 2θ = 4° to 40° at a continuous scan rate of 2.5°/min. 
For CFZ-HCl crystals - data was collected on a Rigaku Miniflex 600 in the Bragg-Brentano 
geometry. The data was collected from 5° – 40°, 2θ with 0.02° steps and a 1.00 s detection time.  
Single Crystal X-ray Diffraction. Diffraction data for CFZ-HCl (both polymorphs and CFZ-
2HCl was collected on a Bruker D8 Venture equipped with a four-circle kappa diffractometer and 
Photon 100 detector. An Iμs microfocus Cu source supplied the multi-mirror monochromated 
incident beam. Diffraction data for CFZ-HCl-2MeOH was collected on a Bruker Kappa/ApexII 
CCD with Molybdenum source. A combination of Phi and Omega scans were used to collect the 
necessary data. A single crystal was picked and mounted on a 0.3mm loop using paratone oil.  The 
samples was cooled to 100 K in a nitrogen supplied Oxford 700 Cryostream.  Data was integrated 
using SAINT and absorption corrected using SAINT/SADABS v2014/4 or SAINT/SADABS 
v2014/2. The final structure was solved using SHELX-2014-4 or SHELX-2014-6. 
Curvature of Biocrystals. The diattenuation images obtained using Polarization microscopy were 
used to quantify for curvature of biocrystals using a ThreePointROI plugin for ImageJ. Briefly, three 
points were marked along the maximum Feret’s length of the high diattenuation signal of the crystal 
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which was used by the plugin to draw a circle through the three points and accordingly provide a 
radius of the circle (r). Curvature for this circle is then defined as κ = 1/r. Co-linear points that 
define an impossible circle resulted in a circle with r = “-1” or “2147483647” pixels and were 
marked as κ=0. A line was then drawn through the three points used to generate the circle to 
generate a chord of length (x) for that circle. Using the length of the chord and the radius, the angle 
formed by the biocrystal arc through that circle was then computed using the formula – θ = 2sin-
1(x/2r). The arc length of the biocrystal was then computed as L = θ.r where θ is in radians. Linear 
curvature density was computed as κ/L. 
Qualitative Bending of Synthesized Crystals. Crystals that were about 2 mm long and ~20 µm 
thick were isolated from the crystallization solution and manipulated to demonstrate the crystal’s 
elasticity. Crystals were placed on a microscope slide in a small amount of water to prevent the 
crystal from moving off the slide. A pair of tweezers and a crystallization probe were used to 
manipulate the crystals. Video of this procedure was taken with a Leica M205 C stereo microscope.  
4.3 Results 
4.3.1 Flexibility of Biocrystals 
The physical morphology of biocrystals were analyzed from by harvesting peritoneal and 
alveolar Mφs from an 8-week CFZ-fed mouse, Appendix A.2. Through brightfield microscopy, 
several cell-associated dark red crystals were identified, some of which were surprisingly curved 
(Figure 4.2a). Moreover, after 10 minutes, the crystals turned over likely due to mechanical forces 
exerted by its parent Mφ (Figure 4.2a). Upon closer inspection, we observed that another biocrystal 
in close proximity to the curved biocrystal also had a minor curvature that straightened out when the 
curved biocrystal flipped (Figure 4.2a). In light of this empirical evidence, we further characterized 
the biocrystals for their curvature (κ) within or isolated from Mφs (Figure 4.2b). The curvature per 
unit length (κ/L) of biocrystals was significantly higher when present in peritoneal Mφs (4.8-fold 
change in mean) or alveolar Mφs (3.6-fold change in mean) compared to when isolated from Mφs. A 
greater number of biocrystals were found to be inherently straight or having zero curvature when 
isolated (26) than when present in peritoneal Mφs (10) or alveolar Mφs (18) (Figure 4.2b). Such a 
reduction in curvature of isolated biocrystals is indicative of forces acting on the crystals by Mφs.  
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4.3.2 CFZ-HCl polymorph I – Biomimetic Crystals 
The primary component of the biocrystals is CFZ-HCl, thus it was hypothesized the 
inherent crystal structure of CFZ-HCl may play a role in the flexibility (being able to adopt non-
linear morphologies) and elasticity (being able to return to the straight conformation) of the 
biocrystals. A synthetic crystallization route was developed to grow CFZ-HCl crystals with a similar 
crystal structure to the biocrystals. The synthetic CFZ-HCl crystals form dark red rectangular plates 
(Figure 4.3a) that closely resemble the crystal habit and color of the biocrystals (Figure 4.3b) as 
observed with brightfield microscopy. The CFZ-HCl crystals can grow to be much larger than the 
biocrystals allowing for optimal structural characterization. The p-XRD (Figure 4.3c) suggests a 
strong agreement in the observed peaks of CFZ-HCl with those from the biocrystals previously 
reported.26 Both samples show strong preferential orientation of the crystals along the (001) face. 
The most intense peak on the p-XRD spectra is the (002) peak due to a systematic absence at (00l) 
when l=2n for Pbca space groups. Thus, the synthesized CFZ-HCl crystals are a suitable model for 
characterizing the mechanical behavior of the biocrystals. 
Figure 4.2. (a) Peritoneal macrophages from a CFZ-fed mouse with the curvature of the curved 
biocrystal marked with dotted lines (white arrows show cell membrane, black arrows mark the 
crystal in physical contact with the first curved crystal). Scale bar – 10 μm. (b) Curvature per unit 
arc length (κ/L) of biocrystals in peritoneal Mφs or alveolar Mφs or when isolated from splenic 
Mφs. (n=100 biocrystals, * - p<0.005. The wider and thick horizontal line indicates the Mean of 
the distribution whereas the other smaller two lines  indicate the Mean ± SE. Number in brackets 
indicates the number of biocrystals measured to have zero curvature. 
(b) (a) 
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Single crystal XRD was also performed to determine the crystal structure of CFZ-HCl. The 
CFZ-HCl crystals grow in an orthorhombic Pbca space group with unit cell parameters; a=10.266 Å, 
b=19.828 Å, and c=24.156 Å, α=β=γ=90° and Z=8 (CCDC number: 1497722). One CFZ and one 
HCl molecule make up the asymmetric unit (Figure 4.4a). Cl3 hydrogen bonds with the CFZ 
through two N-H···Cl interactions. The data set was solved to 99.8% completeness. Some water 
was incorporated into the crystal structure that caused disorder in the isopropyl group, and the water 
had an occupancy of 0.13. A summary of the unit cell parameters and diffraction data can be found 
in Table 4.1.  
A key design feature of the CFZ-HCl crystal structure is the corrugated packing along the 
(001) face (Figure 4.4b,c). One CFZ-HCl molecule makes up one step of the zig-zag and together 
the steps make up one corrugated sheet. The steps of the zig-zag are held together with C-H···π and 
C-H···Cl interactions highlighted by light blue dotted lines and orange solid lines respectively 
(Figure 4.4b). Cl3 is situated in the crease of the zig-zags and serves an anchor by coordinating with 
3 additional molecules strengthening interactions within the crease and coordinating with adjacent 
sheets. These interactions are in 3 nearly perpendicular directions. Weak dispersive bonding between 
Figure 4.3. (a) Optical micrograph of synthesized CFZ-HCl crystals and (b) harvested biocrystals 
from a CFZ-fed mouse spleen. (c) Powder X-ray diffraction data from both biocrystals and CFZ-
HCl crystals. Both samples display preferential orientation favoring the (001) face. The diffraction 
data from 2θ=8-40° is zoomed in for convenient comparisons. 
(b) (a) (c) 
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the sheets of the zig-zags from π···π interactions between the aromatic rings is also present (grey 
dotted lines, Figure 4.4b). Cl1 forms a C-H···Cl interaction that creates a ribbon of CFZ molecules 
when you look down the b-axis. When viewed along the c-axis this interaction is located in the 
crease and it stabilizes interactions between the sheets of the zig zag. The weak multi-directional 
interactions are located at critical parts of the zig-zag and support the previously proposed design 
rules for crystal elasticity.27 The angle between the corrugated steps is ~82°. Face indexing of the 
crystal during XRD showed that the (001) face is the largest surface and which corresponds to the 
previous p-XRD data. The projection of the (001) face is shown in Figure 4.4c to better show the 
corrugated packing. 
4.3.3 Impact of Bending Crystals 
Interestingly, while harvesting CFZ-HCl crystals for single crystals XRD, the crystals would 
noticeably bend when force was applied to pick up the crystals. As soon as the force was removed 
the crystals would promptly return to their original linear morphologies. Subsequently, video 
microscopy was performed of bending crystals with tweezers to further demonstrate their observed 
elastic response. Crystallization experiments yielded a very wide size distribution of crystals out of 
which crystals between 500 µm and 2 mm long and ~20 µm thick were chosen. The CFZ-HCl 
crystals typically lie with the (001) face normal to the substrate (Figure 4.5a). When a slight force was 
Figure 4.4. (a) Asymmetric unit of CFZ-HCl displayed as an ellipsoid plot with 50% probability. 
The atomic positions for all non-hydogen atoms are labeled. (b) One section of the corrugated 
packing with solid orange lines indicating C-H···Cl interactions, C-H···π indicated with a light blue 
dotted line and π···π interactions indicated by light grey dotted lines (unit cell looking along the c-
axis). The molecules are displayed as capped sticks with the hydogen atoms removed for better 
visualization of the crytals packing. (c) Crystallographic projections of packing along the (001) face 
showing the corrugated packing. The projection is made up of  2 x 2 x 0.5 (a x b x c) unit cells. 
(c) (a) (b) 
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applied, the crystal rotated 90° about the a-axis (Figure 4.5b). When a force was applied to the (001) 
face, the crystal bent (Figure 4.5c-d) and assumed its original shape upon removal of the force 
(Figure 4e). The crystal arched again when a second force was applied, Figure 4.5f. As such, the 
crystals can be bent many times without noticeable deformation to the crystal. In one experiment a 
crystal was bent 8 times without noticeable deformation. However, upon applying a larger force, the 
crystal snapped and the crystalline fragments adopted the original straight configuration.  
To confirm the elastic deformation of CFZ-HCl, polarization microscopy was performed as 
a way of measuring the photoelastic phenomena that is commonly observed with application of 
stress and development of strain.32 In this particular study, linear dichroism could be measured using 
hardware configured on an 
epifluorescence-brightfield microscope 
(Appendix A.2). 33, 34  Crystals were imaged 
under polarized light following which the 
anisotropy in transmittance and 
importantly, the azimuth – defined as the 
polarization orientation that results in 
maximum transmittance were computed 
(Figure 4.6)35. Crystals were first identified 
as regions with low transmittance (Figure 
4.6ac). Given the structural packing of 
CFZ-HCl lattice and absence of 
polycrystalline elements in the biocrystals, 
the azimuth distribution was expectedly 
isotropic across the crystal plane when 
unstressed and straight (Figure 4.6b). In 
contrast, the azimuth was anisotropic in 
the elastically deformed region of the 
crystal wherein two approximately 
orthogonal azimuthal orientations were 
measured (Figure 4.6d). In the inward 
region, the azimuth was perpendicular to 
Figure 4.5. (a-d) A CFZ-HCl crystal was bent by 
applying a force with a crystallization probe while 
the crystal was held stationary against a pair of 
tweezers. While the crystal is bent it is thought that 
the angle between the corrugated packing on the 
(001) face decreases on the concave side and 
increases on the convex side of the crystal. (e) The 
force was removed and the crystal quickly regained 
the original position before (f) another force was 
applied to the crystal. Scale bar is 100 µm. 
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the long axis of the crystal whereas in the 
outer region, the azimuth was retained along 
the long-axis of the crystal as observed in the 
straight crystals. Such anisotropy is clearly 
indicative of a stress network resulting in the 
development of an elastic strain through the 
crystal.36 As such, given the extent of cross-
interactions within the crystal lattice as 
described before (Figure 4.4), the 
development of an elastic stress-strain 
network through an expectedly isotropic 
crystal structure was easily accomplished and 
verified through photoelastic azimuth 
measurements.  
Further, no differences in vibrational 
spectra (Raman) were evident before and after 
bending at the point of maximum curvature in 
these crystals (Figure A2.1). Naturally curved 
crystals also showed no differences in 
molecular vibrations compared to the 
reference CFZ-HCl crystals. Finally, the 
melting point for CFZ-HCl was measured to 
be 275°C (Figure A2.2), which is 53 °C degrees higher than CFZ while other salts of CFZ also have 
melting points <246 °C.37 As indicated by their melting points, the salts of CFZ are more stable than 
CFZ. The stabilization of CFZ as CFZ-HCl within mammalian cells therefore favors the formation 
of a highly stable crystalline polymorph and as reported here has appropriate structural packing 
features that allow it to adapt to intracellular mechanical stressors.  
4.3.4 Salt Screen 
Clofazimine is a weakly basic drug, and salt formation is initiated by a proton transfer to the 
imine nitrogen in CFZ (Figure 4.7). In a previous study where 6 salts of CFZ were grown and 
Figure 4.6. (a) Computed transmittance Image 
of a (a-b) straight vs. (c-d) bent crystal. 
Calibration bar in (a,c) shows the range of 
transmittance. Dark regions (with low 
transmittance) follow the crystal with the dotted 
tangential line from one edge of the crystal 
confirming the curvature in the crystal. Azimuth 
– polarization orientation of maximum 
transmittance overlayed on the transmittance 
image indicating unidirectional axes in the (b) 
straight crystal while in the (d) bent crystal, 
there is a bidirectional axes depending on the 
direction of compressional (inward bending 
edge leads to an orthogonal axes) or tensile 
stress (outward bending edge leading to a 
longitudinal axis).  
(a) (b) 
(c) (d) 
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analyzed, all the salts exhibited similar hydrogen 
bonding between the CFZ and the counter 
ion.37 The scheme in Figure 4.7 shows the 
expected proton transfer and hydrogen bonding 
to the Cl- ion at high and low pH. The 
crystallization landscape of CFZ and HCl salts 
was explored as solvent, concentration and 
crystallization environment were varied. 
Crystallization was induced through solvent 
evaporation conducted in 20 mL glass vials and 
single well microfluidic platforms.38 Prior work 
indicates that microfluidic platforms facilitate 
the growth and identification of solid forms not 
observed in an initial off-chip experiments, 
possibly by changing the rate of supersaturation 
or decreasing the nucleation rate in a small 
volume.38-40 In glass vial experiments, solvent evaporated through a small hole poked in parafilm that 
covered the vial while in the microfluidic chip the solvent evaporated slowly through the PDMS. 
The microfluidic platform used in this work has been previously described.38, 41 Crystallization 
experiments were conducted in methanol and acetonitrile, where the solubility of CFZ is sparingly 
soluble. 
Crystallization from Methanol. Slow evaporation of a 2 mM CFZ and 0.1 M HCl methanol 
solution in a glass vial yielded long, thin, red rectangular plates near the edge of the solution. After a 
few days, very dark red rectangular plates were observed at the bottom of the glass vial, Figure 4.8. 
The crystals were extracted and XRD was used to determine the identity of the crystals. The long 
thin needles had a orthorhombic unit cell that matched previously reported data for CFZ-HCl;42 
however the crystals did not diffract well enough to collect a full data set to publishable standards. 
The dark red crystals harvested from the bottom of the vial were found to be a polymorph of the 
biomimetic CFZ-HCl crystal structure which we designate as CFZ-HCl polymorph II. When the 
same crystallization solution was allowed to evaporate in the microfluidic device, only a few crystals 
were observed and the crystals had the same crystal habit as CFZ-HCl polymorph I. A different 
Figure 4.7. Chemical structure of clofazimine 
with pKa of the nitrogen and hydrochloric acid.  
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concentration of CFZ in methanol was probed 
to determine the solid form dependence on 
concentration. Immediately after an 8mM CFZ 
and 0.4M HCl solution was prepared in 
methanol block-like red crystals were observed 
on the side of the glass vial (Figure 4.8). The 
crystals were a CFZ-HCl salt that incorporated 
2 methanol molecules (CFZ-HCl-2MeOH) 
within the crystal structure. The solvent 
incorporation in the crystal structure was 
attributed to the rapid crystallization at high 
concentrations, so further experimentation at 
higher species concentrations was not pursued. 
When this solution was crystallized in a 
microfluidic platform no crystals were 
observed. 
Crystallization from Acetonitrile. Slow 
evaporation of a 2 mM CFZ and 0.1 M HCl 
acetonitrile solution in a glass vial resulted in 
small dark red crystals suspended in the 
crystallization solution. The crystals had the 
same unit cell as CFZ-HCl polymorph II, but 
were much smaller. Crystallization of this 
solution in a microfluidic platform resulted in dark purple prismatic crystals, Figure 4.8. The crystals 
were cut from the microfluidic platform with a razor blade and harvested for XRD. The crystals 
were a higher order salt; a CFZ salt with two exogenous chlorine atoms (CFZ-2HCl). 
Crystallographic data for all crystal structures can be found in Table 4.1. 
 4.3.5 Structure Determination and Analysis 
CFZ-HCl polymorph II. The asymmetric unit of CFZ-HCl polymorph II is made up of one 
CFZ molecule with N1 protonated and one Cl atom. There are two hydrogen bonds between N1-
H···Cl3 and N2-H···Cl3 with bond distances of (D, d, θ: 3.153Å, 2.32Å, 167° and 3.197Å, 2.41Å, 
Figure 4.8. Crystallization experiments 
conducted in glass vials yielded 3 solid forms, 
two of them not previously reported: CFZ-HCl 
polymorph II and CFZ-HCl-2MeOH. 
Crystallization in microfluidic platforms yielded 
a new solid form not found in vial based 
experiments CFZ-2HCl. 
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171°, respectively), Figure 4.9. There are two asymmetric units per unit cell and the ion pair 
crystallizes in the triclinic P ͞1 space group. Although there are no other hydrogen bonding 
interactions, there may be weak dispersive interactions (C-H···Cl) between Cl1 and the propyl group 
on a neighboring CFZ and Cl3 
and neighboring CFZ. The 
crystal has long π···π 
interactions along the (111) 
face, Figure 4.9. The distance 
between the ring centroids is 
3.769(1)Å, which is 
exceedingly far for π···π 
stacking interactions.43, 44 The 
phenyl rings provide some 
steric hindrance which does 
not allow the CFZ molecules 
to come into closer contact. 
CFZ-HCl polymorphs 
I and II seem to have different 
supramolecular features, even 
though the hydrogen bonding 
is very similar. Both crystals 
are largely held together by 
weak electrostatic interactions 
(C-H···Cl) with Cl3 and Cl1 
interacting with neighboring 
CFZ molecules. One unique 
feature of the polymorph I 
crystal structure is that the 
CFZ molecules π···π stack 
into a corrugated structure that 
allows the crystal to elastically 
Figure 4.9. Asymmetric unit of CFZ-HCl solid forms plotted as 
50% ellipsoids. The hydrogen bonding interactions are shown 
with orange dotted lines. The packing of several molecules for 
each crystal structure are shown. In all cases, the CFZs seem to 
create a layered structure with packing hindered by the phenyl 
rings of CFZ. In the CFZ-HCl polymorph structure the packing 
seems to be along the (111) face, while the other two structures 
show alignment up the b-axis. 
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deform when a force is applied and return to the original structure when the force is removed.45 
Elasticity within CFZ-HCl polymorph I is a unique property governed by the crystal packing and 
intramolecular interactions.27 Polymorph II does not have the necessary crystal packing features to 
allow for elastic crystals.  
CFZ-HCl-2MeOH. The asymmetric unit of CFZ-HCl-2MeOH is made up of one CFZ 
molecule with N1 protonated and hydrogen bonded to a Cl molecule and two methanol molecules. 
Cl3 is hydrogen bonded to N1 and N2 in a similar fashion to the non-solvated solid forms with N1-
H···Cl and N2-H···Cl bonds (3.168 Å, 2.33 Å, 174° and 3.231 Å, 2.36 Å, 168°, respectively), Figure 
3. One of the methanol molecules is disordered over two positions and Cl3 is hydrogen bonded to 
the methanol molecules through a O-H···Cl bond (3.030 Å, 2.18 Å, 172° and 3.093 Å, 2.28 Å, 160°, 
for positions A and B respectively), Figure 4.9. The second methanol was highly disordered and 
atomic positions could not be resolved. The electron density from the disordered methanol was 
removed from the structure using the SQUEEZE function. The crystal grows as an orthorhombic 
Pbcn space group with 8 asymmetric units per unit cell. 
CFZ-2HCl. CFZ-2HCl is comprised of one CFZ molecule with N1 and N4 protonated and 
2 Cl molecules that are held together with hydrogen bonds. One of the hydrogen bonds is similar to 
the CFZ-HCl (1:1) salts where Cl3 is hydrogen bonded to N1 and N2 through N-H···Cl (3.147 Å, 
2.27 Å, 176° and 3.139 Å, 2.30 Å, 173°, respectively), Figure 4.9. The second hydrogen bond is 
between N4 and Cl4 with a N-H···Cl (2.949 Å, 2.13 Å, 170°), Figure 4.9. Cl4 has occupancy of 0.76. 
The crystal grows in a P21/c monoclinic space group with 4 asymmetric units in the unit cell. There 
are no other hydrogen bonding interactions within the crystal structure. The crystal is likely held 
together with weak electrostatic interactions with all the Cls participating. As in polymorph II, steric 
hindrance from the phenyl rings prevents the CFZ molecules from packing close enough to π···π 
stack along the (010) face.  
The protonation of the second nitrogen was not necessarily expected because the computed 
pKa of that nitrogen is 2.31.
42 The formation of this solid form within the microfluidic device could 
be due to nucleation suppression within the small volume.38-40 If enough solvent evaporates, the 
remaining solution will become increasingly acidic until the second nitrogen is protonated. Growth 
of CFZ-2HCl was repeatable within a microfluidic platform, but was not observed in our glass vial 
experiments. 
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4.4 Conclusion 
The inherent structural packing features of CFZ-HCl within biocrystals contribute to their 
elasticity and naturally adjustable curvature. As such, formation of biocrystals mediated by Mφs leads 
 
 
CFZ-HCl (I) CFZ-HCl (II) CFZ-2HCl  CFZ-HCl-2MeOH  
empirical formula C27H23.26Cl3N4O0.13 C27H23Cl3N4 C27H23.76Cl3.76N4 C29H31Cl3N4O2 
formula weight 512.18 509.84 537.46 573.93 
temperature (K) 100 100 100 100 
wavelength (Å) 1.54178  1.54178 1.54178 0.71073 
crystal system Orthorhombic Triclinic Monoclinic Orthorhombic 
space group Pbca P-1 P21/c Pbcn 
a (Å) 10.266 8.754 12.073 14.151 
b (Å) 19.828 12.178 15.270 13.796 
c (Å) 24.156 12.589 14.612 28.103 
α (°) 90 63.841 90 90 
β (°) 90 80.740 111.04 90 
ϒ (°) 90 83.940 90 90 
volume (Å
3
) 4917.10 1188.00 2514.20 5486.20 
Z 8 2 4 8 
densitycalc (mg/m
3
) 1.384  1.425  1.420 1.390  
absorption 
coefficient (mm
-1
) 
3.562  3.679  4.229 0.369  
θ range for data 
collection (°) 
3.659 to 68.333 3.944 to 68.391 3.923 to 68.286 2.062 to 25.348 
data/restraints/para
meters 4500 / 134 / 365 4332 / 0 / 315 4613/0/329 5025 / 33 / 362 
completeness to 
theta (%) 
99.8 99.4 99.8 99.9 
goodness-of-fit of F
2
 1.069 1.074 1.052 1.040 
final T indices [I > 
2σ(I)] 
R
1
 = 0.0392 
wR
2
 = 0.0982 
R
1
 = 0.0357 
wR
2
 = 0.0800 
R
1
 = 0.0463 
wR
2
 = 0.0816 
R
1
 = 0.0319 
wR
2
 = 0.0823 
CCDC 1497722 1507038 2507039 1507040 
 
Table 4.1. Crystallographic information for all solid forms. 
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to the development of elastic and curved crystalline elements with structural packing features that 
showcase the classical design rules designated for organic crystal flexibility[27–30]. The presence of 
CFZ biocrystals in the Mφ endows them with potent anti-inflammatory characteristics46, 47 and 
specific fluorescent48 and photoacoustic49, 50[ signatures for cellular optical tracking. Such dual 
therapeutic and diagnostic (theranostic) applications make biocrystals a potent cellular device that 
could be harnessed for biomedical applications. Mφ-mediated crystallization is an important example 
of how these cells self-assemble a crystal with features that allow for easier adaptability to the 
mechanical environment of the cell, thereby allowing a massive drug loading within the cell. As such, 
mechanical flexibility of exogenous elements within cells could be a critical design parameter toward 
engineering organic intracellular constructs to endow cells with unnatural yet stable and beneficial 
features for therapeutic applications. Finally, viscoelasticity and related mechano-transductive 
elements are innately connected to Mφ inflammatory phenotype51, 52. As such, the characterization of 
intracellular mechanical properties could be important for cell-based mechano-biological 
applications leading to a new class of pharmaceutics: mechano-pharmaceutics. 
Additionally, the crystallization screen was successful at identifying other solid forms of 
biomimetic clofazimine hydrochloride salts. Solvent, concentration, and crystallization condition 
(glass vial or microfluidic platform) all played a role in solid form elucidation. Analysis of the crystal 
packing showed similarities between the hydrogen bonding and electrostatic interactions with all 
solid forms compared to the bio-accumulated CFZ-HCl crystal. However none of the solid forms 
discussed had the unique corrugated crystal packing within the crystals. Despite the multitude of 
interactions driven by the salt chloride ions within the crystal, the solid forms are structurally 
different from the original biomimetic CFZ-HCl crystal as well as the biocrystal itself.  
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Chapter 5 
Additive Manufacturing of Pharmaceuticals by Meniscus-
guided Coating 
5.1 Introduction 
 The United States Federal Drug Administration (U.S.F.D.A.) has encouraged pharmaceutical 
companies to improve their manufacturing procedures through process analytical technology and 
quality-by-design procedures.1 An outcome of this effort has been the development of a new 
manufacturing strategy in the pharmaceutical industry called additive manufacturing. Through 
additive manufacturing a 3-dimensioanl object is made by the addition of multiple 2-diemnsional 
objects, or layer-by-layer assembly. Additive manufacturing has been implemented in industries such 
as aerospace and medical device. One of the most attractive features of additive manufacturing is 
continuous processing and the ability to quickly change manufacturing conditions without the need 
to create new tooling.1 Coupled with online monitoring of product quality, it is possible to monitor 
product and quickly adapt process parameters to meet specifications.2 Additive manufacturing can 
lead to a decrease in waste and could solve some of the scale-up issues seem when moving from 
bench to pilot or full-scale production. A potential benefit of additive manufacturing is the potential 
of personalized medicine. Currently pharmaceutical companies determine the average recommended 
dosage based on clinical studies, however ideally the dosage and time-release profile would be 
tailored to the patient’s needs. Batch technologies do now allow for much flexibility in processing 
conditions without large changes to product quality. 
 Additive manufacturing has been previously demonstrated for pharmaceuticals. Many of the 
techniques are based on droplet-on-demand technology and utilize similar technology as an ink jet 
printer.3-5 Additional additive manufacturing techniques could help broaden the scope of and impact 
of use in the pharmaceutical industry. 
 Meniscus-guided coating is a solution deposition technique commonly used for alignment of 
small molecule organic semiconductors and conductive polymers. Through meniscus-guided coating 
thin crystalline layers of material are deposited on a substrate. Controlling process parameters, such 
as concentration of the solution and shearing speed the crystallinity and morphology of the film can 
be manipulated. In prior work, growth of thin films have been documented to trap or stabilize 
  
54 
 
metastable polymorphs6 and grow with different crystal morphology7 likely impacting the 
physiochemical properties of the material. This work explores meniscus-guided coating of 
pharmaceuticals as an additive manufacturing technique. Aspirin and ellipticne were used as model 
compounds to determine process parameters and printability for pharmaceutical thin films. 
5.2 Experimental 
5.2.1 Meniscus-guided coating 
Solution Preparation. Solutions of aspirin in ethanol were prepared by measuring out amounts 
of aspirin and adding the appropriate amount of ethanol to achieve the needed concentration in 
small vials. Aspirin would first be weighed out in a small scintillation vial, and then that value was 
divided by the desired concentration to obtain the volume of ethanol needed. The ethanol was then 
pipetted into the scintillation vial. The vial was lightly agitated to promote dissolution. It was 
important to be cautious to prevent solution from making contact with the lid of the vial in order to 
prevent contamination.  
For ellipticine, the same method was applied. An appropriate amount of ellipticine was 
weighed out in a small scintillation vial, and then that value was divided by the desired concentration 
to obtain the volume of DMSO that needed to be added. The DMSO was then pipetted into the 
scintillation vial and the vial was lightly agitated to promote dissolution. This solution was then used 
so that dilutions could be made in order to obtain more samples of varying concentrations. 
Substrate Preparation. A 1x1 cm SiO2 wafer was cleaned with toluene, acetone, and 
isopropanol, and was placed exposed to an oxygen plasma. Once the machine was started and the 
gas stabilization phase was turned on, the pressure was checked to ensure that it is around 200 
mmHg. The plasma cleaned substrate was then spin coated with a solution of 5 wt% pullulan in 
water at 1200 rpm for 30 seconds. 
Printing on Wafer. The computer programs EP901 and StreamPix were opened. In EP901, the 
settings were changed to Remote Mode and the motor must be turned on. The motor apparatus, the 
camera overhead light, the background light, blade and stage vacuums, and the heating system were 
also turned on. The heating system was set to 25 °C. On StreamPix, PixelLink and AVTMako 
cameras should both be turned on. “Set new sequence in RAM” was also selected. The SiO2 wafer 
was placed on the stage, on top of the vacuum, and aligned using the AVTMako camera. The 
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cleaned Si blade was placed on the blade vacuum, with the reflective side facing down, towards the 
stage. The blade was aligned with the wafer by looking at the AVTMako and adjusting the 
orientation of the blade until it was parallel to the wafer. The blade was then lowered to the wafer 
until the two almost touch, then it was raised by 10 µm. Through EP901, the blade was aligned to 
around 1 mm of the wafer front and the printing speed was then changed to 0.1 mm/s, or any of 
the speeds that were being screened. A pipette was used to pull 5 µm of aspirin solution and was 
dropped in a line on the wafer. As the printing speed decreased, more solution was needed to be 
deposited onto the substrate. On EP901, the printer was then set to drag 25 mm to the right. On 
SteamPix, the recording was then started. This procedure was repeated for all concentrations of 
aspirin. After each print of aspirin, the recording was stopped and the file was saved into .sequence 
and .jpg formats. Before starting to record a new print, “Set new sequence in RAM” had to be 
selected. For ellipticine, the same steps were repeated, however the temperature of the printing stage 
was set to 110 °C. 
Taking and Making Videos. The .jpg files from a print were imported into a Windows Movie 
Maker new file. The duration was set to 1.00 and the file was saved as a Windows Movie Maker file. 
The images were then deleted from the Windows Movie Maker program and the new movie file was 
imported. The speed was then adjusted so that the overall movie duration was approximately 10 to 
15 seconds long. This file was then saved again in a Windows Movie Maker file. 
5.2.2 Characterization 
Polarized Optical Microscopy. The light source was turned on and the dial was adjusted 
accordingly to the amount of light needed. The substrate was placed on the stage with a 10x 
magnification and then NIS Elements Viewer was opened on the computer. The live viewer was 
then enabled. The cross polarization was adjusted until the display of the microscope was as dark as 
possible. Likewise, the stage was rotated until the crystals displayed on the screen were also as dim as 
possible. The fine tune dial was turned until the image displayed on the screen was as clear as 
possible, and then the image was saved. The same was repeated for the 50x magnification. 
Powder X-ray Diffraction. Data was collected on a Rigaku Miniflex 600 in the Bragg-Brentano 
geometry. The data was collected from 5° – 40°, 2θ with 0.02° steps and a 8.00 s detection time. The 
entire SiO2 wafer/polymer/crystalline film was placed in a standard powder diffraction sample 
holder and the crystalline film was flush with the surface of the sample holder. 
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Single Crystal X-ray Diffraction. Diffraction data for ellipticine polymorph II was collected on a 
Bruker D8 Venture equipped with a four-circle kappa diffractometer and Photon 100 detector. An 
Iμs microfocus Cu source supplied the multi-mirror monochromated incident beam. Diffraction 
data for CFZ-HCl-2MeOH was collected on a Bruker Kappa/ApexII CCD with Molybdenum 
source. A combination of Phi and Omega scans were used to collect the necessary data. A single 
crystal was picked and mounted on a 0.3mm loop using paratone oil. The samples was cooled to 100 
K in a nitrogen supplied Oxford 700 Cryostream.  Data was integrated using SAINT and absorption 
corrected using SAINT/SADABS v2014/4 or SAINT/SADABS v2014/2. The final structure was 
solved using SHELX-2014-4 or SHELX-2014-6. 
5.3 Results 
5.3.1 Meniscus-guided coating Setup 
The meniscus-guided coating setup is composed of a SiO2 blade coated with a crystalline 
self-assembled monolayer (octadecyltrichlorosilane) to prevent wetting of the ink solution. The 
blade was moved with a linear stage motor digitally programed. The substrate is a SiO2 wafer coated 
with a water soluble and biocompatible polymer, pullulan. Pullulan is a polysaccharide polymer often 
used in orally dissolving films for pharmaceuticals or novelty items such as mints. The solution that 
Figure 5.1. Meniscus-guided coating diagram and chemical structures of aspirin, ellipticine, and 
pullulan. Depicting a crystalline film of aspirin or ellipticine on a pullulan substrate. As the coating 
blade is moved, the drug is solution crystallized to form a thin film of the model drug. 
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is sheared over the substrate was aspirin dissolved in ethanol or ellipticine dissolved in dimethyl 
sulfoxide (Figure 5.1).  
5.3.2 Aspirin Thin Films 
Processing conditions can play a large role in the packing and morphology of crystalline thin 
films. Concentration of the ink solution and the rate of shearing were varied to determine the effect 
of these processing conditions on film morphology. A morphology diagram was created to visualize 
the effect of these parameters on film morphology. Non-dimensional units were used for the 
diagram. Concentration of the drug in solution was reported as a weight percent which equals the 
weight of the drug divided by the total weight of the solution and the blade shearing speed was 
reported as a capillary number (Ca) which equals the shearing velocity multiplied by the viscosity and 
divided by the surface tension. Standard values for ethanol the viscosity and surface tension of 
ethanol are used in this calculation. Optical micrographs along with video taken during the printing 
are used to determine the morphology regime (Figure 5.2). For aspirin thin films there are two 
primary regimes, spherulitic growth and oriented growth. Between these regimes there is a transition 
region where both morphologies are observed. Spherulitic growth occurs by a two-step mechanism 
where a thin film of the drug in solution is deposited across the substrate. After a few seconds, 
spherulites begin to form and crystal growth is isotropic form the nucleation point. On the other 
hand, in the oriented growth regime crystal growth tracks the meniscus during printing. In this 
regime crystals growth is mainly in the direction of the blade shearing. Optical polarized microscope 
images of films in each regime can be found in Figure 5.2. At lower concentrations and faster 
shearing speeds (higher Ca number), spherulitic growth is expected. At higher concentrations and 
slower shearing speeds (lower Ca number) oriented growth is expected. From the morphology 
diagram, shearing speed seems play a larger factor in the film morphology.  
Manipulating process parameters can change the thickness of the crystalline films. Shearing 
speed and concentration were varied and film thickness was measured with profilometry (Figure 
5.2). Shearing speed was manipulated over almost four orders of magnitude from 3,000 µm/s to 5 
µm/s while the concentration of the solution was held constant at 5 mg/ml. At slower speeds the 
film thickness increases and the standard error in the measurement is much larger due to uneven 
morphology of the oriented films. At faster speeds the film thickness decreases until it reaches a 
critical value of about 50 nm. After this point, even as shearing speed increases the film thickness is 
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not affected. This could be due to dewetting of the solution from the polymer substrate. Varying the 
shearing speed resulted in aspirin thin films with thicknesses from 50 nm to over 1.5 µm. 
Concentration of aspirin solutions varied from 2 mg/ml to 100 mg/ml with shearing speed held 
constant at 0.1 mm/s. Higher concentration solutions yielded higher concentration films with most 
films having oriented morphology. Concentration and film thickness have a linear relationship. In 
this study, films were printed on pullulan and plasma treated SiO2. Wetting properties for the 
ethanol on both of these substitutes is slightly different resulting in a different slope of the 
Figure 5.2. Morphology diagram of aspirin thin films as a function of weight percent and 
capillary number. Optical polarized microscopy images are used to represent each film 
morphology. Film thickness was measured as a function of shearing speed and concentration of 
drug in solution. In the thickness versus speed graph the concentration of aspirin was 5 mg/ml 
and in the constant velocity graph the shearing speed was 100 µm/s. 
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concentration thickness 
graph (Figure 5.2).  
Grazing 
incidence X-ray 
diffraction (GIXD) and 
powder X-ray 
diffraction (PXRD) 
data was collected for 
the spherulitic and 
oriented aspirin films, 
Figure 5.3. The 
collected spectrum 
were compared to the 
simulated power 
pattern for aspiring 
(CCDC ASCALA01). 
Data for both 
morphologies 
correspond well the 
simulated pattern, 
indicating they have the 
same crystal packing. The films are preferentially oriented with the (100) face oriented out of plane. 
5.3.3 Ellipticine Thin Films 
Ellipticine is an anti-cancer drug with only one reported polymorph. A morphology diagram 
was created to visualize the effect of concentration and shearing speed on film morphology, Figure 
5.4. In a similar fashion to aspirin distinct morphologies are observed. Dots are observed at high 
shearing speed and low concentration. The formation of dots is likely due to spherulites breaking 
into smaller pieces and dewetting from the substrate. Spherulites are not independently observed, 
but spherulites coupled with needles are observed. When both needles and spherulites are observed 
at low concentration the needles are randomly oriented and do not preferentially grow in the 
Figure 5.3. Gixd, powder diffraction and simulated powder 
diffraction data for aspirin films. The simulated data 
corresponds to ASCALA01 from the CCDC. The numbers 
at the top of the graph indicate the (hkl) values of the 
diffraction peak. Data from both spherulites and oriented 
films correspond well with the simulated diffraction data. 
The films have preferential orientation with the (100) face 
growing out of plane. 
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direction of meniscus-guided coating. As the concentration increase and speed decreases the needles 
become more prevalent and the amount of spherulites decrease. The needles will also preferentially 
grow in the direction of meniscus-guided coating. With continued increase in concentration and 
reduction in speed, the needles grow into plates. At high concentration and the slowest printing 
speed, multi-phase crystals are observed where yellow needles grow on top of the plate morphology, 
Figure 5.4.  
GIXD from samples of plates with yellow needles, plates, and needles with spherulites was 
collected to determine if the crystal morphology has the same molecular packing. The data was 
plotted with a simulated powder pattern for the reported crystal structure of ellipticine (CCDC 
ELLIPT). Data from the thin films did not match the reported crystal structure. A single crystals of 
a new polymorph of ellipticine was found and characterized (Appendix Table A.1). The simulated 
powder pattern of the new polymorphs was compared with the thin films spectra, Figure 5.5. The 
Figure 5.4. Morphology diagram of ellipticine films as a function of capillary number and 
concentration. Several morphologies are observed with polarized optical microscope images to 
represent each of the regimes. 
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spectra for plate and 
needles with spherulites 
morphology correspond 
well to each other and 
compare well with the 
peaks of the new 
polymorph. The plates 
with yellow needles have 
diffraction peaks that 
mostly align with 
polymorph II but a few 
that align well with 
polymorph I. From this 
information, the yellow 
needles that grow on top 
of the plates are thought to 
be polymorph I, while the 
underlying film is 
polymorph II. 
5.4 Conclusion 
 Through this work, 
meniscus-guided coating was demonstrated as an additive manufacturing technique for 
pharmaceuticals. Meniscus-guided coating allowed for the control of film morphology, film 
thickness, and molecular stacking. Aspirin was used as a model compound to demonstrate the effect 
on film morphology and thickness as concentration and shearing speed were varied. Film thickness 
ranged from 50 nm to 1.5 µm. Ellipticine was used as a model compound to demonstrate control 
over molecular packing. Thin films of ellipticine polymorph II were primarily obtained, however at 
high concentration and low shearing speed multi-phase films of both polymorph I and II were 
observed. Both model compounds displayed different film morphologies as process parameters 
were varied, although the molecular arrangements for these morphologies were the same. Although 
much more work should be done to determine the viability of meniscus-guided coating for industrial 
Figure 5.5. GIXD and simulated powder diffraction data for 
ellipticine films. The simulated polymorph I data corresponds 
to ELLIPT from the CCDC. The numbers at the top of the 
graph indicate the (hkl) values of the diffraction peak. The red 
(hkl) values corresopond to peaks from polymorph II while 
black (hkl) values correspond to polymorph I. Ellipticine films 
with needle, or needle and spherulites seem to be polymoph II 
while the plates are composed of mainly polymorph II with a 
small amount of polymorph I. Along with the morphology 
diagram, this data can be used to grow a specific phase and 
morphology of ellipticine. 
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pharmaceutical application, meniscus-guided coating has proven to be a promising technique for 
controlling small molecule molecular arrangement for pharmaceutical thin films.  
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Chapter 6 
Conclusions and Future Directions 
6.1 Expanding Microfluidic On-chip Characterization 
The crystallization platforms used in the Kenis group have evolved from traditional 
thick polydimethylsiloxane (PDMS) based devices to multi-layer platforms made from cyclic 
olefin copolymer and thin PDMS layers. These engineered platforms allowed for on-chip 
characterization with polarized optical microscopy and Raman spectroscopy.1, 2 The 
platforms have normally closed valves that allow for specific and precise fluid routing. Polar 
organic solvents such as alcohols and acetonitrile are compatible with the platforms, and in 
recent work platforms made from a perfluoropolyether instead of PDMS provide a much 
wider range of solvent compatibility to include benzene and hexane.3 Part of this work was 
to determine if the microfluidic platforms are compatible with X-ray diffraction.  
The first challenge of doing X-ray diffraction on-chip is the need for large, single, 
unblemished crystals. Typically, the crystallization screens result in a mixture of small poorly 
formed crystals and single crystals. To improve crystallization outcomes, a crystal seeding 
approach was taken to decouple crystal nucleation and growth. Crystal seeding resulted in 
larger higher quality crystals as compared to the control experiments with no seeds. Crystal 
seeding also allowed for growth of only one polymorph of the carbamazepine – 4-
hydroxybenzoic acid cocrystal compared to the control experiment where two polymorphs 
were observed. Diffraction data was collected from multiple crystals and merged to create a 
complete electron density map.4 The resulting crystal structure was comparable quality to the 
previously reported data.5 This demonstration underlies the powerful capability of on-chip 
characterization. This technique would be largely useful for small crystals that are not 
amenable with traditional X-ray crystallography, since data can be taken from multiple 
crystals and merged to create a whole dataset. 
6.2 Microfluidics for Solid Form Screening  
In previous work microfluidic platforms have been used to screen for polymorphs, 
salts, and cocrystals of APIs.1-3 This previous work was done to validate that microfluidic 
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systems could achieve the same crystallization outcomes as off-chip screens. However, often 
the crystals grown in the microfluidic platform were larger and better quality than the crytals 
off-chip. Part of my work was to determine if microfluidic platforms could be used for solid 
form discovery, instead of simply verification. A model system where 3 cocrystals of 
piroxicam – 2,5-dihydroxybenzoic acid were reported with Raman spectra but no crystal 
structure. 6 Although Raman spectroscopy is good for differentiating solid forms, it is not 
able to provide structural information about the composition or the packing of the solid. 
Single crystal X-ray diffraction is an ideal technique to gain structural information about the 
solid. The goal of this work was to determine if a crystallization screen on a microfluidic 
platform would yield crystals of high enough quality for X-ray diffraction. A solvent screen 
and concentration screen yielded four different solid forms, two of them previously 
reported.6 Three of the crystals were high quality and characterized by X-ray diffraction. 
Interestingly, one of the previously reported crystals was a solvated cocrystal that 
incorporated an impurity, acetone, into the crystal structure even though acetone was not the 
solvent used during the crystallization. Through this work, microfluidic platforms are 
validated for improving crystal quality, when compared to the previous crystal screen. 
Additionally, the microfluidic screen identified two new solid forms of the cocrystal system. 
6.3 Solid Form Screening for Biomimetic Crystals  
After realizing that bioaccumulated crystals of clofazimine hydrochloride (CFZ-HCl) 
are bent by their environment, a collaborative project between the Kenis group and the 
Rosania group at the University of Michigan began. The goal of the work was to determine 
the underlying mechanism behind the flexibility of the bioaccumulated crystals. The 
biocrystals as well as CFZ-HCl crystals grown with the typical protocol were too small for 
single crystal X-ray diffraction.7 A solvent and concentration screen was performed on and 
off-chip. Four solid forms of clofazimine hydrochloride were observed: biomimetic CFZ-
HCl polymorph I, CFZ-HCl polymorph II, CFZ-2HCl, and CFZ-HCl-2MeOH. Three of 
the diffraction quality crystals were grown on-chip and one of the solid forms was only 
observed on-chip. The inherent elasticity of the crystal was determined to be caused by two 
unique features of the crystal packing (1) weak multi-directional bonds and (2) corrugated 
packing.8, 9 The additional solid forms form the screen may open up new therapeutic avenues 
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and again the use of microfluidic platforms in the screen helped elucidated additional solid 
forms.  
6.4 Microfluidic Implementation in the Pharmaceutical Industry  
Although there are many reasons to use microfluidic technology in the 
pharmaceutical industry, the industry has been slow adopt this technology. Lack of dedicated 
vendors selling microfluidic platforms, protocols outlining how the product should be used, 
and training on platform use could be the largest hurdle. Many microfluidic platforms claim 
to be easy to use or require few ancillaries, however an experienced used is often still 
required to consistently set-up the experiment. Additionally, each candidate drug often 
requires a slightly different crystallization protocol based on solubility or ease of 
crystallization and a standard microfluidic platform may not be able to accommodate these 
diverse needs. Even though there are existing challenges preventing microfluidic platforms 
from entering the pipeline in the pharmaceutical industry, microfluidics seem to be a 
beneficial supplementary technique for solid form screening or growth of single crystals.  
6.5 Meniscus-guided Coating for Additive Manufacturing  
Additive manufacturing of pharmaceuticals currently is dominated by drop-on-
demand technology where active pharmaceutical ingredients (APIs) are dissolved in a solvent 
or polymer mixture and sequentially dropped onto an edible substrate.10, 11 Manufacturing 
advantages to this technique are continuous processing, allowing for online monitoring and 
quality-by-control, and easy manipulation of process parameters. This would allow 
pharmaceutical companies to create personalized dosages and specific time release profiles, 
compared to the traditional one-size fit all approach. Meniscus-guided coating to create 
pharmaceutical thin films was explored as a technique to expand the additive manufacturing 
space. Aspirin and ellipticne were explored as model compounds to determine process 
parameters and printability for creating thin films. Printing conditions were varied to change 
the film thickness of aspirin from 50 nm to over 1.5 µm. Concentration and shearing 
velocity were varied to create a morphology diagram for both drugs. In both cases, distinct 
regions of film morphology were observed ranging from thick plates (high concentration, 
low speed) to anisotropic growth of spherulites or multi-directional needles (low 
concentration, high speed), and transition zones between them. For aspirin and ellipticine 
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both morphologies (oriented and spherulites) have the same crystal packing, although 
interestingly the crystal packing for the ellipticine film corresponds to an unreported second 
polymorph. Through this work meniscus-guided coating was demonstrated to be a useful 
technique for growing thin pharmaceutical films, and expanding the manufacturing 
approaches for pharmaceutical additive manufacturing. 
6.6 Future Directions of Meniscus-guided Coating for Pharmaceuticals  
There are many possible directions for meniscus-guided coating of pharmaceuticals. 
(1) Determine increase in solubility. Nanosizing is a technique currently employed in the 
pharmaceutical industry to increase the solubility of poorly water soluble drugs, however 
currently the methods to create nanosized particles are high energy and lead to a wide 
dispersion of particle size. Creating nanoscale thin films via meniscus-guided coating may be 
able to address the current challenges. (2) Creating multi-layered films. One challenge when 
formulating multicomponent API tablets or capsules is finding processing conditions that 
are appropriate for both APIs, another challenge is preventing the APIs from cocrystallizing. 
Creating multi-layered films separated by thin polymer sheets could avoid these challenges. 
(3) Roll-to-roll printing. Continuous manufacturing is of interest in the pharmaceutical 
community, to deduce the time and effort associated with batch processing. Roll-to-roll 
printing is a common technique used from the manufacturing of newspapers to organic 
semiconductors. This technique could be implemented for scaling the production of 
pharmaceutical thin films. (4) Online monitoring of product quality. Implementing analytical 
techniques into the production line could reduce product waste and improve manufacturing 
procedures. 
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Appendix A 
  
A.1 Platform Fabrication and Assembly 
Negative photoresist masters were fabricated using SU-8 2050. Two unblemished wafers 
(which will serve as the control layer and fluid layer masters) were rinsed with acetone and isopropyl 
alcohol, then dried with nitrogen gas and placed on a 95oC hotplate for at least 2 minutes so that 
they completely dry. Once the wafers were dried, SU-8-2050 was poured on the center of the wafer, 
then placed on the spin-coater. The control layer master was programmed to spin for 35 seconds at 
2500 rpm. The fluid layer master was programmed to spin for 35 seconds at 2800 rpm. Once the 
wafers were coated, they are set aside for 5 minutes. The wafers were soft baked uncovered for 1.5 
minutes at 65oC then 6.5 minutes at 95oC then allowed to cool. The appropriate mask and wafer 
were paired and a solid quartz block was placed on top of the mask. The assembly was exposed to 
the UV lamp for 23 seconds. Care was taken to not place the mask backwards and to not damage 
the quartz crystal. The masters were then hard bake for 1.5 minutes at 65oC then 6.5 minutes at 
95oC, then allowed to cool. The masters were developed in a PGMEA bath for roughly 5 minutes 
with occasional stirring. Once all of the photoresist was dissolved, the wafers were washed with IPA 
and dried with nitrogen. Finally, the wafers were silanize to reduce adhesion of the PDMS used it 
the next stage (Figure A.1). 
The control layer was made my mixing PDMS part A and B in a 5:1 ratio, and the fluid layer 
wass made by mixing PDMS part A and B in a 15:1 ratio. The PDMS was vigorously stirred to 
ensure good mixing of the monomer and cross-linker, and then placed in the vacuum chamber to 
eliminate air in the PDMS. The masters were cleaned using tape to remove any particulate matter or 
fibers that may have fallen on them during storage. PDMS was then poured over the fluid and 
control layers and any bubbles or particulate matter was removed with a pipette. The fluid layer was 
spin coated at 1550rpm for 35 seconds and the control layers at 1150rpm for 35 seconds. The 
wafers were baked on a hot plate at 80°C, for 12 minutes and 5 minutes respectively. A sheet of 
COC and the control layer were activated with plasma. The COC was quickly aligned on top of the 
control layer and any bubbles were smoothed out. The assembly was baked at 80°C for 3 minutes, 
making sure to smooth out any additional bubbles that formed. The COC-control layer combination 
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was peeled off of the master, making sure not to let the device rip. Holes were drilled into the COC-
control layer assembly to provide access to the vacuum lines and allow for operation of the valves. 
The COC-control layer sheet was aligned with the fluid layer under a microscope, heated at 80°C for 
5 minutes, and placed in an oven at 60°C overnight. The COC-control layer-fluid layer assembly was 
peeled off the master and holes were drilled to provide fluid inlet ports. The assembly was then 
placed on a COC substrate layer and was ready to use. 
A.2 Biocrystals 
A.2.1 Biocrystal Harvesting 
Mouse Model for Generating Biocrystals. Mice (4 week old, male C57Bl/6) were purchased from 
the Jackson Laboratory and acclimatized for 1 week in a specific-pathogen-free animal facility. Animal 
care was provided by the University of Michigan’s Unit for Laboratory Animal Medicine (ULAM), and 
the experimental protocol was approved by the Committee on Use and Care of Animals. Clofazimine 
(CFZ) was dissolved in sesame oil to achieve a concentration of 3 mg/ml, which was mixed with 
Powdered Lab Diet 5001 to produce a 0.03% drug to powdered chow feed. 
Peritoneal Lavage to obtain Peritoneal Macrophages. Peritoneal lavage was done 8 weeks after 
the initiation of CFZ treatment. Mice were euthanized by exsanguination while deeply anesthetized by an 
Figure A.1. (a) A 3x3 array of single well microfluidic platform. (b-h) Cross-sectional view of 
chip fabrication.  
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intraperitoneal injection of ketamine (100 mg/kg)/xylazine (10 mg/kg) followed by sterilization of the 
outer skin with 70% of ethanol. A small incision was made along the midline of the abdomen followed by 
abdominal skin retraction up to the thoracic boundary and the animal extremities to expose the intact 
peritoneal wall. A smaller incision was then made on the peritoneal wall to expose the cavity. The entire 
peritoneal cavity was washed with ice-cold sterile Phosphate Buffered Saline (PBS) + 5% of Fetal Bovine 
Serum (FBS) (5–10 ml) and collected as peritoneal exudate. The exudate was then centrifuged (100 x g 
for 5 min, 4 °C) and suspended in 1.5 ml of PBS + 5% of FBS. Cells were counted using a 
hemocytometer for viable cells using Trypan Blue and for biocrystal-containing cells. For preparation of 
microscopy slides, a 20 μl drop of cell suspension was placed on a glass slide and allowed to dry 
overnight in the dark. The following day, a single drop of Prolong® Gold was added to the dry slide and a 
cover slip was applied prior to imaging. 
Alveolar Lavage to obtain Alveolar Macrophages. Mice were euthanized as described above and 
the trachea was surgically exposed and cannulated with an 18G luer stub and the lungs were lavaged to 
obtain alveolar exudate by instilling PBS containing 0.5 mM of EDTA in 1 ml aliquots for a total of 6 ml. 
The alveolar exudate fluid was centrifuged (400 x g, 10 min, 4 °C) and resuspended in RPMI 1640 media. 
Viable (using Trypan Blue staining method) and biocrystal containing cells were counted using a 
hemocytometer followed by preparation of microscope slides as mentioned above. 
Isolation of Biocrystals. At 8 weeks post-drug feeding, mice were euthanized as described above 
and spleens were harvested and cut open to prepare tissue homogenate in phosphate-buffered saline 
(PBS). The tissue homogenate was sonicated for 30 min and centrifuged (100 x g for 1 min) to 
remove large cell debris. A solution of 10% sucrose in PBS was added to the acquired supernatant 
and the mixture was centrifuged (100 x g). The resulting supernatant was centrifuged (3200 x g for 20 
min) to pellet drug inclusions which were then suspended in 2 ml of 10% sucrose in water (w/v). 
Biocrystals were further purified using a three-layer discontinuous gradient (50, 30, and 10% sucrose 
(w/v) in PBS) centrifugation method (3200 x g for 30 min, no brakes). 
Microscopy of Biocrystals. Optical micrographs of crystals were taken with a Leica M205 C 
stereo microscope. The combination brightfield and diattenuation LC-Pol-Scope microscope set-up 
is a custom built microscopic imaging system similar to the birefringence LC-PolScope designed by 
Oldenbourg et al, but without the polarization analyzer. Our LC-PolScope is built on the Nikon 
Eclipse Ti inverted microscope, with the computer-controlled universal compensator placed 
between the interference filter (546±22 nm) and condenser lens. Illuminating light is narrowed to 
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546 nm by the interference filter, and the light is linearly polarized by passing it through a universal 
compensator, allowing for the diattenuation of the sample to be measured. The LC in the universal 
compensator is controlled by Image J “Micro-manager” software (Vale Laboratory, UCSF) and is 
automatically rotated to produce polarized light at 0°, 45°, 90° and 135° angles, respective to the 
horizontal, during image acquisition. The image maps of diattenuation, mean transmittance, and 
angle of high transmittance are generated by image analysis algorithms followed by calibration. 
Brightfield and fluorescence images were captured using the Nikon DS-U3 camera and 
Photometrics CoolSnap MYO camera system, respectively, under the control of Nikon NIS-
Elements AR software. Microscopy slides of samples were prepared as mentioned before. 
A.2.2 Characterization of Biomimetic CFZ-HCl Crystals 
Differential Scanning Calorimetry (DSC). Samples were analyzed using a TA Instruments 2910 
MDSC system equipped with a refrigerated cooling unit. All experiments were performed by heating the 
pre-weighed samples at a rate of 10 °C/min under a dry nitrogen atmosphere. Temperature and enthalpy 
of the instrument were calibrated using high purity indium standard.  
Raman Spectroscopy. Crystal samples were synthesized and physically manipulated before being 
transferred onto a pure silicon wafer. Confocal Raman microscopy was performed using a WITec 
Figure A.2. Differential Scanning Calorimetry of CFZ-HCl. Melting Point indicated with curved 
arrow – 275.80 °C. 
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alpha300 R equipped with a near-IR 785nm to minimize clofazimine’s fluorescence signal. Samples 
were positioned on the stage for spectral data acquisition and were observed using the reflectance 
illumination mode of the microscope. Once positioned, the 2 µm diameter 785 nm laser illumination 
spot was directed to the sample, and the Raman spectrum was acquired. Raw data were background 
subtracted from the signal obtained from pure silicon wafers and further baseline-corrected using 
Origin®. 
 
 
 
 
Figure A.3. (a) Raman Reflectance Brightfield images of (top) short CFZ-HCl crystals and 
(bottom) bent portion of a long CFZ-HCl elastic crystal. Blue arrows indicate moving away 
from the confocal plane used to obtain the point spectra of CFZ-HCl. (b) Raman Spectra of 
CFZ-HCl reference crystals with crystals that were subjected to mechanical bending (before 
and after) and crystals that had an inherent curvature. 
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A.3 Ellipticine Polymorph II 
  
Table A.1 Crystallographic information for ellipticine 
polymorph II. 
 
 
ELP (II) 
empirical formula C17H14N2 
formula weight 246.30 
temperature (K) 100 
wavelength (Å) 1.54178 
crystal system orthorhombic 
space group Pbca 
a (Å) 16.802 
b (Å) 7.249 
c (Å) 20.798 
α (°) 90 
β (°) 90 
ϒ (°) 90 
volume (Å
3
) 2533.280 
Z 8 
densitycalc (mg/m
3
) 1.292 
absorption coefficient (mm
-1
) 0.077 
θ range for data collection (°) 2. to 25.377 
data/restraints/parameters 2331/0/178 
completeness to theta (%) 99.9 
goodness-of-fit of F
2
 1.141 
final T indices [I > 2σ(I)] R
1
 = 0.0585 
wR
2
 = 0.1166 
 
